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Résumé 
Dans cette étude, la stabilité de préparations intraveineuses de cyclosporine (0.2 et 
2.5 mg/mL dans NaCl 0.9% ou dextrose 5%) entreposées dans des seringues de 
polypropylène, des sacs de polypropylène-polyoléfine et des sacs de vinyle acétate 
d‟éthylène a été évaluée. Une méthode HPLC indicatrice de la stabilité à base de méthanol 
a été développée et validée suite a des études de dégradation forcée. Les solutions évaluées 
ont été préparées de façon aseptique, puis entreposées à 25°C. La stabilité chimique a été 
évaluée par HPLC et la stabilité physique a été évaluée par inspection visuelle et aussi par 
diffusion dynamique de la lumière (DLS). Tous les échantillons sont demeurés stables 
chimiquement et physiquement dans des sacs de polypropylène-polyoléfine (>98% de 
cyclosporine récupérée après 14 jours). Lorsqu‟entreposés dans des seringues de 
polypropylène, des contaminants ont été extraits des composantes de la seringue. Toutefois, 
aucune contamination n‟a été observée après 10 min de contact entre la préparation de 
cyclosporine non-diluée et ces mêmes seringues. Les préparations de 2.5 mg/mL 
entreposées dans des sacs de vinyle acétate d‟éthylène sont demeurés stables chimiquement 
et physiquement (>98% de cyclosporine récupérée après 14 jours). Toutefois, une 
adsorption significative a été observée avec les échantillons 0.2 mg/mL entreposés dans des 
sacs de vinyle acétate d‟éthylène (<90% de cyclosporine récupéré après 14 jours). Une 
étude cinétique a démontré une bonne corrélation linéaire entre la quantité adsorbée et la 
racine carrée du temps de contact (r
2
 > 0.97). Un nouveou modèle de diffusion a été établi. 
En conclusion, les sacs de polypropylène-polyoléfine sont le meilleur choix; les seringues 
de polypropylène présentent un risque de contamination, mais sont acceptables pour un 
transfert rapide. Les sacs de vinyle acétate d‟éthylène ne peuvent être recommandés à cause 
d‟un problème d‟adsorption. 
 
Mots-clés : Cyclosporine, stabilité, seringue, sac pour perfusion, dégradation forcée, 
adsorption
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Abstract 
In the present study, the stability of intravenous cyclosporine preparations (0.2 and 
2.5 mg/mL in 0.9% sodium chloride injection or 5% dextrose injection) stored in 
polypropylene (PP)  syringes, polypropylene–polyolefin (PP-PO) bags and ethylene vinyl 
acetate (EVA) bags was evaluated. A methanol-based high-performance liquid 
chromatography (HPLC) method was developed and validated to be stability-indicating by 
stress degradation tests. The test solutions were aseptically prepared and stored at 25 °C. 
Chemical stability was evaluated by HPLC assay. Physical stability was assessed by visual 
inspection and a dynamic light scattering (DLS) method. All samples were chemically 
stable (> 98% of recovered cyclosporine) and physically stable when stored in 
polypropylene–polyolefin bags for 14 days. When stored in polypropylene syringes, some 
impurities were leached. However, no leaching was detected when the syringes were 
exposed to undiluted intravenous cyclosporine for 10 minutes. The preparations of 2.5 
mg/mL were chemically and physically stable as stored in ethylene vinyl acetate bags for a 
period of 14 days (> 98% of recovered cyclosporine), while significant cyclosporine 
adsorption occurred on the samples of 0.2 mg/mL (< 90 % of recovered cyclosporine) after 
14 days.  Kinetic study showed that good linear correlations were achieved by plotting the 
adsorption amount versus square root of contact time (r
2
 > 0.97). A novel diffusion model 
was established and  successfully predicted long-term drug stability. In conclusion, 
polypropylene–polyolefin bags were the best choice;  syringes were inferior because of 
leachables.  However, they were safe for preparation and transferring undiluted intravenous 
cyclosporine. Ethylene vinyl acetate bags cannot be recommended due to cyclosporine 
adsorption. 
 
Keywords : Cyclosporine,  stability,  syringe,  infusion bag,  stress degradation,  adsorption 
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Chapter one 
1 Introduction: cyclosporine formulations, chemistry 
and quality control 
1.1 Cyclosporine chemistry and formulation 
Cyclosporine (Cya) is a potent immunosuppressive agent in organ transplantation to 
avoid rejection, as well as for the treatment of various auto-immune diseases. Commercial 
products include oral and intravenous formulations {Novartis, 2011a #1007}. The stability 
and compatibility with containers are basically related to its physicochemical nature and 
formulation composition. The following introduction will focus on the properties of Cya 
drug substance and drug products.  
1.1.1 Nomenclature, structure and property of Cya 
Cya (CAS 79217-60-0) or Cya A is a cyclic undecapeptide peptide (formula: 
C62H11N11O12; molecular weight: 1202.6 g/mol). The synonyms  such as cylosporin, 
Cyclosporine, ciclosporin are also used in different countries {Hossan, 1987 #1008}. 
As shown in  
A 
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B  Modified from {Wenger, 1985 #1001} 
Figure 1.1 Structure of cyclosporine, it is composed of 8 natural amino acid residues 
with L-configuration and 3 non naturals. The achiral amino acid sarcosine (Sar or MeGly) 
is present at position 3 and D- Alanine (Ala) can be found at position 8. Importantly, an 
unusual amino acid (4R)-4-[(E)-2-butenyl]-4, N-dimethyl-threonine (MeBmt) at position 1 
is required for its biological activity {Hossan, 1987 #1008}. The conformation of Cya has 
been extensively investigated by X-ray diffraction and NMR techniques. Because of intra-
molecular hydrogen bonds, Cya has a rigid conformation either in  solid crystal state or in 
solution {Hossan, 1987 #1100}. Furthermore, the side chain of MeBmt stands out and is 
primarily responsible for the immunosuppressive activity{Kessler, 1985 #1009}. Likewise, 
the amino acid residues Abu, MeGly, MeLeu, MeLeu, MeVal at position 2, 3, 4, 10, and 11 
are also related to the biological activity {Quesniaux, 1986 #1010}. 
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B  Modified from {Wenger, 1985 #1001} 
Figure 1.1 Structure of cyclosporine   
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Figure 1.2 Structure of dihydrocyclosporine 
 
Due to the cyclic structure and inherent intra-molecular hydrogen bonds (Figure 1.1 
B), cyclosporine is very stable under normal conditions. However, degradation occurs 
under stress conditions. Several degradation pathways have been reported for the 
formulations under shelf life conditions {Bonifacio, 2009 #1011}: dehydration on olefinic 
bond and even loss of the MeBmt side chain; chain opening and oligopeptide formation, 
and N-O peptidyl shift  to form isocyclosporine {Oliyai, 1994 #1012}. Another known 
degradant is dihydrocyclosporine  (Figure 1.2). In the stability study of cyclosporine oral 
solution, it has been found that isocyclosporine (Figure 1.3) could be produced in acid 
medium {Kumar, 2001 #1017}.  
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Figure 1.3 Structure of isocyclosporine 
Considering the presence of hydrophobic amino acid residues and its neutral nature, 
cyclosporine is highly hydrophobic. It is poorly soluble in water and slightly soluble in n-
hexane, soluble in acetone, ether and chloroform. White prismatic crystal (melting point: 
148-151
o
C) can be obtained from saturated acetone solutions  {Hossan, 1987 #1008}. 
Cyclosporine displays high intestine permeability {Amidon, 2003 #1101} and poor 
aqueous solubility (0.04 mg/mL at 25°C), as a result, it is classified as BCS II drug 
substance according to biopharmaceutical classification system (BCS) {Ismailos, 1991 
#1018;Augustijns, 2000 #1019}. 
1.1.2 History and therapeutic applications of Cya  
The discovery of Cya was a cutting-edge revolution in immunopharmacology.   
Since 1961, a combination of azathioprine and corticosteroids had been the 
predominant immunosuppressant in organ transplantation. However, its application is 
limited due to the main side effects such as depression of the bone marrow and increased 
susceptibility to infections. Corticosteroid has its drawback in clinic applications as well. It 
inhibits T lymphocytes and is used as an anti-inflammatory agent, but the action is non-
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selective, inevitably generating adverse side effects such as diabetes, avascular necrosis of 
bones and increased tendency to infections {Upton, 2001 #1020} .  
Cya turns out to be a better option due to its stronger immunosuppressive activity and 
much lower toxicity. It is the first drug that exhibits selective immunoregulation of T cells 
without excessive toxicity. However, there is still a therapy limitation originating from the 
nephrotoxicity, hepatotoxicity and incomplete control of chronic rejection {Naesens, 2009 
#1175;Erdem, 2011 #1072}. Many efforts have been made to reduce the toxicity by 
developing novel formulations {Muller, 2006 #1179;Czogalla, 2009 #1099;Muller, 2006 
#1179}. 
Cya was initially obtained from the fungus Tolypocladium inflatum, an extract of soil 
sample in Norway {Dreyfuss, 1976 #1103}. Several metabolites of this fungus, including 
Cya and other analogues (B, C, D, G and H), have been isolated. The main component Cya 
A, now named as Cya, was found to have strong immunosuppressive activity. In the 
following years, it was successfully utilized in preventing organ rejection in kidney 
transplant and liver transplant {Calne, 1978 #1104;Starzl, 1981 #1105}. In 1983, it was 
approved as an immunosuppressant to prevent graft rejection in transplantation by the U.S. 
Food and Drug administration (FDA) {Upton, 2001 #1020}. Currently, it has also been 
used in most autoimmune diseases, such as psoriasis, severe atopic dermatitis, pyoderma 
gangrenous, chronic autoimmune urticaria, and rheumatoid arthritis. Additionally, Cya has 
been formulated as an ophthalmic eye drop emulsion and widely applied for dry eye 
treatment {Salib, 2006 #1177}. Its application for cardiac disease treatment has become 
another focus of interest {Mott, 2004 #1180}.   
Cya as well as its analogs Cya B, C, D, G and H were extracted from fungal 
metabolites followed by chromatography separation {Ruegger, 1976 #1109;Dreyfuss, 1976 
#1103;Ruegger, 1976 #1109}. The total synthesis was first reported in 1984 {Wenger, 1984 
#1110}. The successful synthesis of Cya and its analogues provided good understanding of 
the structure-activity relationship {Wenger, 1985 #1001}. However, none of the analogues 
showed greater potency than Cya itself. Among them, Cya G, in which norvaline at the 2 
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position replaces alpha-aminobutyric acid (Abu) in Cya, appears to be an efficacious 
immunosuppressant and is less nephrotoxic than Cya {Henry, 1995 #1112;Jeffery, 1991 
#1111}. 
1.1.3 Cya formulation 
Table 1.1 Main commercial products of cycolsporine 
Product Company Main excipient 
Sandimmune® 
Soft Gelatin Capsule Novartis Corn oil 
Sandimmune® 
Oral Solution Novartis Olive oil 
Sandimmune® 
Injection Novartis Cremophor® EL  
Neoral® 
Soft Gelatin Capsule Novartis 
Corn oil-mono-di-triglycerides Cremophor® RH  
40  
DL-α-tocopherol USP 
Neoral® 
Oral Solution Novartis 
Corn oil-mono-di-triglycerides, 
Cremophor® RH  40  
DL-α -tocopherol USP 
 Propylene glycol USP 
Restasis® 
 Allergan, Inc. 
Glycerin; castor oil, Polysorbate 80, 
Carbomer copolymer type A 
 
Due to poor solubility in water, Cya is generally formulated as suspensions or 
emulsions for oral and parental administration. The main commercial products in the 
market are listed in Table 1.1.  
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The first marketed product under the trade name Sandimmune® was developed by 
Sandoz, now Novartis {Novartis, 2011 #1007}.  The oral products include Sandimmune® 
Soft Gelatin Capsules and Sandimmune® Oral Solution. They consist of Cya, alcohol and 
oil and are in the form of oil-in-water emulsions. Such formulation feature leads to erratic 
absorption depending on food intake, fatty content and gastrointestinal tract secretion. The 
bioavailability variability between patients and within an individual patient over time gives 
rise to particular concerns of potential toxicity and dosage monitoring {Yocum, 2000 
#1114}. To overcome the drawback of emulsion formulation, a modified formulation in 
form of microemulsion has been developed and marketed as brand name Sandimmun 
Neoral®.  The microemulsion can be formed immediately when the formulation contacts 
with aqueous environment. This feature enables fast drug release in the gastrointestinal 
tract and the absorption becomes less influenced by concomitant food intake and diurnal 
rhythm. Thus the intra-patient and inter-patient variability of all pharmacokinetic 
parameters can be reduced to some extent {Kovarik, 1994 #1115;Novartis, 2011b #1116}.  
Cya demonstrates considerable P-glycoprotein (P-gp) efflux in intestinal absorption, 
which is another aspect for poor and variable bioavailability {Fricker, 1996 #1117} .  The 
bioavailability of Sandimmun Neoral® may be in the range from 10% to 60%.  Because 
Cya has a narrow therapeutic window index {Armstrong, 2001 #1118;Shaw, 1999 #1119}, 
the microemulsion Cya exhibits a pronounced initial plasma peak, which is unfavourable 
considering its therapeutic index. In the last decade, novel formulations have been 
developed to reduce toxicity by designing controlled release delivery system, such as solid 
lipid nanoparticles and micelle delivery systems {Muller, 2006 #1179;Aliabadi, 2006 
#1120}. 
Intravenous Cya (Sandimmune® Injection) has been developed in the form of 
microemulsion, using polyoxyethylated castor oil as emulsifier {Novartis, 2011 #1116}. 
There are already generic Cya products available in the market, including Cicloral 
(Sandoz/Hexal), Gengraf (Abbott), Deximune (Dexcel Pharma Ltd) and Sangcya 
(SangStat ). A topical formulation for treating keratoconjunctivitis sicca has been marketed 
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under the trade name Restasis by Allergan, Inc. {Lallemand, 2003 #1122;Allergan, 2010 
#1181}. Inhaled Cya formulations are currently under clinical development, including a 
solution in propylene glycol and liposome dispersions {Groves, 2010 #1124;Iacono, 2006 
#1182}. 
1.1.4 Pharmacokinetics of Cya 
The absorption, distribution, metabolism and excretion of Cya have been extensively 
documented. The absorption from the gastrointestinal tract is variable due to the 
formulation features and the nature of Cya. After administration of oral Sandimmune, blood 
and plasma concentrations reach maximum 1.0 ng/mL and 2.7-1.4 ng/mL (Cmax ) at about 
3.5 h (Tmax), respectively, while for modified oral Neoral,  Cmax is  59% higher than 
traditional Sandimmune and achieved at about Tmax 2.5 h  {Novartis, 2011 #1116}.The 
bioavailability is 29 % higher than oral Sandimmune. The distribution of cyclosporine 
exhibits multicompartment behaviour, it accumulates in liver, pancreas, lungs, kidneys, 
adrenal glands, spleen and lymph nodes {Novartis, 2011 #1116}. 
Cya is mainly metabolized by cytochrome P-450 enzymes. Even though the drug has 
a complex structure, the identified metabolites are limited and have the intact cyclic 
oligopeptide structure of the parent drug. The major route of elimination is biliary, and only 
6% of the dose is excreted in the urine through the bile {Novartis, 2011 #1116}. 
1.1.5 Administration of intravenous Cya   
Cya Sandimmune
®
 I.V. (Novartis) is an intravenous preparation of Cya. The 
formulation is shown in Table 1.2. 
Table 1.2  Sandimmune
®
 I.V. formulation 
Formulation Cya Ethanol (94% w/w) Polyoxyethylated castor 
oil (Cremophor EL) 
Sandimmune
®
 I.V 
1 mL 
50 mg 278 mg 650 mg 
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Based on the product monograph, the injection solution must be diluted with 0.9% 
sodium chloride injection (NS) or 5% dextrose injection (D5W) before adminstration 
{Novartis, 2011 #1116}. 
1.2 Infusion container 
Large volume parenterals can be packaged in flexible bags, glass bottles or syringes 
when administrated to patient by infusion. As well known, liquid-based dosage is more 
likely to interact with the packaging materials than solid forms. For parenterals, 
contaminants, which may come from the packaging materials or due to the protection 
failure of packaging, can rapidly and completely be introduced into the blood circulation. 
Thus, as required in FDA guideline, injectable drug products represent one of the highest 
risk drug products considering the likelihood of interaction between packaging and 
injections, and more information should be provided  regarding safety and compatibility of 
packaging system {FDA, 1999 #1128}.  
1.2.1 Safety evaluation of packaging containers 
Infusion containers both bottles and bags can be defined as container closure systems. 
According to the FDA guidance documents, four attributes: protection, compatibility, 
safety and performance/drug delivery are required to meet the related regulation {FDA, 
1999 #1128;Albert, 2004 #1183}. 
Containers required to protect drug products from light should be subject to light-
transmission test and meet the specification regulated in USP 34 <661> containers 
{USP34-NF29, 2011b #1004}.  Infusion bags should be also evaluated in terms of integrity.  
The compatibility of containers should be sufficient to maintain the quality of the 
drug formulations. Herein leaching and extraction tests have to be carried out to evaluate 
potential chemicals extracted from containers. Leachable can be inorganic or organic, 
depending on the type of materials used and manufacturing processes. A number of 
analytical techniques can be employed to detect and quantify leached impurities, including 
liquid chromatography (LC), gas chromatography (GC), mass spectrometry (MS), 
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inductively coupled plasma (ICP) spectroscopy {Yu, 2000 #1130}. In addition, other 
changes like pH shifts, precipitate, and discoloration should be inspected, because these 
changes may lead to drug degradation and pose hazardous issues during administration. 
With respect of safety evaluation, container materials should be verified of no 
harmful to human health. It is imperative to have a good knowledge of the material 
composition (e.g. production process, solvents used, potential impurities, polymer 
additives), as well as information of drug substance and excipients, thus having a good 
understanding of potential leachables and possible interaction of these materials with drug 
formulations.  
Finally, performance should be evaluated on the functionality and appropriate drug 
delivery. The point is on improvement of patient compliance, minimum waste, or ease of 
use. Good performance should ensure to deliver the right amount or rate of drug substance. 
For instance, the container should have low water vapour transmission to ensure minimum 
water loss, thus keeping drug concentration consistent {Paula Youngberg webb, 2009 
#1185}.  
1.2.2 Infusion container types 
Infusion containers can be bottle or flexible bags. They are used to prepare or store 
fluid mixtures to be administered to a patient through an intravascular administration set. 
The material used can be glass or plastic.   
1.2.2.1 Glass bottles 
In earlier years, glass bottles were the standard containers for intravenous 
administration, which are gradually replaced by plastic containers or bags due to cost and 
delivery facilitation. However, in the case of special intravenous liquids, glass bottles are 
still a good choice due to the inert chemical reactivity. Glass bottle has various advantages. 
First of all, it is transparent, which is particularly important to inspect particles or 
aggregates when preparing injection or during administration. Besides, glass bottle is 
known as gas-proof and chemically inert to most drugs and excipients.  
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However, glass container has some disadvantages.  It is breakable and the delivery is 
costly. In addition, it must be vented and the administration requires careful monitoring to 
prevent any possible air embolism at the end of the infusion. Also it does not support a 
pressure infusion by using pressure cuff. Drug sorption is still a concern, especially in the 
case of administration of proteins and peptides nutrient {Mizutani, 1984 #1135}. In 
addition, the possible inorganic leachable such as metal ions may affect the stability of  
metal sensitive infusion fluids {Dean, 2007 #1136}. Therefore, it is still necessary to 
evaluate the compatibility of glass material with infusion liquid before use {Sacha, 2010 
#1134}. 
1.2.2.2 Plastic containers 
Currently, flexible plastic bags are predominant infusion containers in the market. 
Compared to traditional glass bottles, plastic infusion bags have lower weight, lower cost 
and several application advantages. Firstly, they are more user-friendly, safer, more healthy 
and more convenient than glass bottles. The flexibility enables the bag to shrink during 
administration and no air interchange is needed. Thus, air embolism can be avoided during 
infusion administration. In addition, it is easier to mix the contents when admixtures are 
required. More importantly, flexibility makes pressure infusion possible. However, barrier 
and sealing property, transparency and chemical inert property are usually inferior to glass 
bottles. As the storage time and temperature increase, a high gas and water permeability 
may cause substantial water evaporation or gas permeation, which will produce 
inappropriate administration. Therefore, numerous specific tests are required to guarantee 
the safety of plastic containers. 
The major types of materials used for parenteral plastic packaging include 
polyvinylchloride (PVC),  polyethylene (PE), polypropylene (PP), ethylene vinyl acetate 
(EVA) {Sacha, 2010 #1134}. 
PVC bags were the first flexible containers used in intravenous administration and 
have dominated the market for many years. The polymer PVC is brittle and very hard, thus 
high amount of phthalate DEHP (bis(2-ethylhexyl) phthalate) has to be added to enhance 
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flexibility. However, the leaching of  DEHP to products has been proven to be a hazardous 
issue. The Environmental Protection Agency (EPA) has classified DEHP as a probable 
human carcinogen {EPA, 2000 #1137}. The FDA also issued a public health notification 
regarding the use of DEHP {FDA, 2011 #1138}. Furthermore, drug sorption on PVC 
containers occurs. {Martens, 1990 #1139;Noh, 2009 #1140}. Up to date, DEHP/PVC 
containers have been banned or restricted in a number of countries (e.g. Germany, Sweden, 
France, Canada, Spain, South Korea and the Czech Republic). On the other hand, there is 
environmental issue arising from PVC disposability. It  produces hydrochloric acids waste 
and dioxin when incinerated {Sittig, 2008 #1186}. 
Table 1.2 Comparative properties of plastic bags 
Modified  from {Sacha, 2010 #1134} 
Property PVC LDPE 
a 
HDPE 
b 
PP EVA 
Compatibility 
with 
drug products 
Poor Good Good Good Fair 
Protection from 
moisture 
evaporation 
Very poor Good Excellent Good Very poor 
Transparency 
characteristics 
Good Fair Poor Fair Fair 
Collapsibility 
characteristics 
Excellent Poor Poor Poor Good 
Disposability Poor Good Good Good Fair 
Heat sterilization Fair Poor Good Excellent Very poor 
a 
LDPE means low density polyethylene.   
b 
HDPE means high density polyethylene. 
14 
 
Most companies instead are using DEHP-free non-PVC materials. Basically the 
alternative materials are biologically inert, plasticizer-free, clear, flexible, non-toxic and 
biodegradable.  
Generally speaking, the drug stability should be highlighted regarding of container 
materials and drug formulations. The properties of plastic bags are illustrated in Table 1.2 
{Sacha, 2010 #1134}.   
Plastic syringe is also used for small dose intravenous administration to paediatric 
patients. The materials typically used are polycarbonate, polyethylene and polypropylene 
{Anes J, 1992 #1142}. In most cases, these syringes have high compatibility with drug 
formulations. However, some potential problems may arise from the silicone lubricant, 
which are incompatible with some drug formulations, for example, silicone may cause 
protein aggregation due to hydrophobic interaction {Jones, 2005 #1143}. In addition, some 
impurities may be leached from uncoated rubber plunger. It has been reported that Eprex○R   
formulation leached some impurities from uncoated rubber of syringe plunger, causing the 
incidence of pure red cell aplasia in chronic kidney disease patients. The investigation 
showed that surfactant polysorbate 80 in the formulation was responsible for the product-
rubber interaction {Yu, 2010 #1144;Boven, 2005 #1187}. 
In conclusion, plastic bags are popularly used due to flexibility and delivery 
convenience. Currently, the standards for plastic containers are less addressed than glass 
ones. Extra tests and efforts are required regarding the interaction between drug product 
and container materials. Practically, application of infusion containers are in dilemma and 
the compatibility is highlighted only when the problems are encountered clinically. 
Currently, the non-PVC containers have been used for the administration of Cya 
intravenous injection. However, their compatibility has rarely been investigated.  
1.3 Drug stability study 
According to the U.S. Pharmacopeia (USP), drug stability is defined as the extent to 
which a drug product retains the same properties and characteristics within specified limits 
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throughout its period of storage and use (i.e., its shelf-life) {USP34-NF29, 2011a #1002}. 
The stability of intravenous injections is affected by the interaction of formulation and 
container materials:  
 The adsorption of drug substance to the surface will lead to drug loss. 
  The leachables from the surface materials to the injection fluid may cause toxicity, 
drug degradation, induce aggregation or precipitation during storage and administration.  
 Gas permeation may cause degradation or other incompatibility. 
 Moisture evaporation leads to inconsistent drug concentration. 
In addition, microbial stability should be examined to avoid contamination. Normally, 
validated aseptic procedure can prevent from microbiological contamination. Therefore, for 
most parenteral products of small molecular drug, stability studies mainly focus on the 
alteration of physical and chemical properties, as well as therapeutic property.   
Drug adsorption is essentially related to the drug property and the container 
composition. The sorption can be caused by electrostatic or hydrophobic interaction. For 
example, the basic drugs can be ionized in acidic medium and tend to be adsorbed on 
negatively charged polystyrene surface, the polar molecules are prone to be adsorbed on 
polar surfaces. The adsorption of lipophilic drugs are usually dominated by hydrophobic 
interactions. The partition of drug in liquid medium or solid material is a determinant 
aspect. Hydrophobic drugs with higher log P have tendency to adsorption on plastic 
surfaces (Palmgren, Monkkonen et al. 2006). 
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Figure 1.4 Adsorption process 
 
As shown in Figure 1.4, the adsorption process includes bulk diffusion, interfacial 
diffusion and uptake. External diffusion refers to the diffusion across the liquid film to the 
solid surface; internal diffusion refers to the liquid contained in the pores of along the pore 
walls; uptake refers to adsorption to active site or mass action {Qiu, 2009 #484}. For 
physical adsorption, the adsorption or uptake to active site is very rapid and the adsorption 
rate is always controlled by external diffusion or internal diffusion rate. The adsorption 
kinetics of drug on packaging materials is seldom studied. Good understanding of 
adsorption mechanism may be expected to evaluate the performance of packaging 
containers regarding drug loss. 
1.3.1 Stability-indicating methods 
Evaluation of pharmaceutical product stability has been addressed in regulations in 
U.S. Food and Drug Administration (FDA), U.S Pharmacopeia (USP), World Health 
Organization (WHO), International Conference on Harmonisation (ICH), and other 
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agencies. These regulations require that the methods for stability evaluation should be 
validated to be stability-indicating.   
According to FDA guidelines, a stability-indicating method is defined as a validated 
analytical procedure that could accurately and precisely measure active pharmaceutical 
ingredient (API) in drug substance or drug products, without interference with degradation 
products, process impurities or other potential impurities {FDA, 2000 #1146}. It is  
recommended that all assay procedures for stability studies be stability-indicating {FDA, 
2000 #1146;Swartz, 2005 #1147}, in which it can detect the changes of drug substance 
properties and measure the active ingredient accurately {Velagaleti, 2007 #1148}. 
 Stability-indicating methods can be specific or selective {Bakshi, 2002 #1149}. The 
former refers to a method that is able to measure unequivocally the drug in the presence of 
all degradation products. The later refers to measuring drug unequivocally, as well as all 
degradation products and impurities. Even though selective stability indicating method is 
time-consuming and costly, it is required when potential safety concerns arise from 
degradation product or impurity. In case of old drugs or drug products, if the degradation 
behaviour is well understood, specific stability-indicating method is sufficient for the 
routine stability evaluation.   
 In order to develop a stability-indicating method, stress degradation (also called 
forced degradation) is required to produce potential degradation products.  It can be 
undertaken under acid and basic hydrolysis, higher temperature above the accelerated 
storage temperature, humidity, photolysis and oxidation. The drug structure dictates its 
degradation behaviour. Compounds like amides, esters, lactams, lactones, etc. are 
susceptible to hydrolysis under acid and base conditions {Velagaleti, 2007 #1148}. Thiols 
and thioethers undergo oxidation even under mild conditions. Compounds with carbonyl, 
nitroaromatic, N-O, double C=C bond, suplfides, alkenes, polyenes, and phenols may 
degrade under light exposure. Oxidation degradation might be catalyzed by trace quantities 
of metal ions. In addition, Environmental changes such as  temperature, pH value, vehicles 
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and impurities released from packaging materials may influence the degradation  {Hovorka, 
2001 #1150}.  
Current guidance documents do not regulate how stress test should be carried out. 
Most practices are performed on a sound scientific basis. Stress degradation conditions are 
optimized depending on the chemical nature of the active ingredient and the type of dosage 
forms. Successful stress degradation should yield representative degradants and control 
appropriate rate in order to meet the requirement of stability-indicating demonstration. 
Importantly, stress degradation may be different from that under shelf-life conditions, thus, 
mild condition is preferred to yield true degradation products. 
In some cases, stress test should be performed both on API and drug products in order 
to understand the influence of excipients on stability. Generally, degradation should not 
exceed 5-15% of API. Extensive degradation may lead to limited relevant products and 
complicated degradation patterns {Klick S., 2005 #1151}. Stability data should be 
evaluated with physical, chemical, and microbiological properties. The US FDA guidance 
defines significant changes for drug or drug products as following  {FDA, 2003 #1152}:   
 Change of  5% in assay during the period of storage.  
 Degradants exceeding specifications.  
 Physical attributes such as color, phase separation, pH and dissolution failing to meet 
specifications.   
Real time stability tests vary with dosage forms. As for parenterals, various aspects 
should be considered, including color, clarity for solutions, particulate matter, pH, sterility, 
and endotoxines. For instance, stability test of suspensions or emulsions for injection 
should include inspection of phase separation, particle size and size distribution.   
1.3.2 Techniques employed in stability-indicating methods 
The traditional titrametric, spectrophotometric techniques have been employed in 
stability tests in pharmacopoeia monographs. However, most of them are lacking of 
specificity or selectivity (Abdel-Fattah, El-Sherif et al. 2010), separation from related 
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substances and impurity identification are usually required. So far, chromatographic 
methods have become predominant in stability assessment {Abdel-Fattah, 2010 #1188}, 
including thin-layer chromatography (TLC), high-performance thin-layer chromatography 
(HPTLC), gas chromatography (GC), HPLC and capillary electrophoresis (CE), etc. TLC is 
effective in identifying degradation products and impurities. However, the variability and 
non-quantitative nature in TLC limit its application. Instead, a novel technique of high 
performance thin layer chromatography (HPTLC) is more accurate and reliable and appears 
powerful in quantitative drug stability tests {Fakhari, 2008 #1154;Abdel-Fattah, 2010 
#1188;Rao, 2011 #1155;Kumar, 2001 #1017;Rao, 2011 #1155}.  GC can be used as 
stability-indicating technique, however, its application is not versatile and restricted when 
the drugs are not volatile or thermally unstable. Up to now, there are few reports on the use 
of GC for stability evaluation. Instead, HPLC has been extensively employed due to the 
attributes of high resolution, sensitivity and specificity. Non-volatile, thermally unstable or 
polar/ionic compounds can be analyzed on HPLC by rational alteration of stationary phase, 
mobile phase or even detector. Based on separation mechanism, HPLC methods are 
classified as normal-phase chromatography (NP-HPLC: using polar stationary phase and a 
non-polar, non-aqueous mobile phase), and reversed-phase chromatography (RP-HPLC: 
using non-polar stationary phase and an aqueous, moderately polar mobile phase). Ion-
exchange chromatography is also utilized to assay ionic substance. Furthermore, the 
multiple choices of detectors facilitate versatile applications. The detectors include 
ultraviolet-visible (UV/VIS), photodiode array (PDA) detector, refractive index (RI) 
detector, fluorescence detector, evaporative light scattering detector (ELSD), 
electrochemical detector, and conductivity detector. PDA collects spectra across a range of 
wavelengths at each retention time, making it more powerful for specificity evaluation and 
impurity identification.    
The application of hyphenated techniques such as gas chromatography-mass 
spectrometry (GC-MS), liquid chromatography-mass spectrometry (LC-MS), liquid 
chromatography-nuclear magnetic resonance (LC-NMR) and capillary electrophoresis-
mass spectrometry (CE-MS) are powerful to identify known and unknown degradation 
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products or impurities {Lee, 1999 #1156;Belal, 2009 #1189;Singh, 2010 #1190;Lee, 1999 
#1156}.  Capillary electrophoresis (CE) is the latest technique applied in stability study, it 
has the advantage of high sensitivity, resolution and high efficiencies with minimal peak 
dispersion {Visky, 2005 #1191;Singh, 2010 #1190}. 
Among the stability-indicating methods, HPLC is cost-effective, high throughput and 
almost universal. The combination with mass spectrometry and PDA facilitates method 
development in   stability study.  
1.3.3 Physical stability 
Physical stability is closely related to dosage forms. Any changes such as phase 
separation, particulate, precipitates and discoloration may cause degradation or increase 
potential risk. Regarding emulsion, liposome and suspension formulations for intravenous 
administration, particle size and particle size distribution are the major stability parameters 
{Wong, 2008 #429}.  
 Particle size can be measured by microscopy, coulter counter, dynamitic light 
scattering (DLS), or laser diffraction (LD) {Wu, 2011 #1160}. The application of each 
technique should take account of accuracy, precision and particle size range. Thus, 
accuracy, precision and sample preparation procedure should be validated. Dynamic light 
scattering (DLS) is a powerful technique to measure particles in the range of 0.3 nm to 10 
μm and the measurement is precise in the range of 10 nm to 1000 nm {Malvern, 2011 
#1202}. This technique is suitable for micelle systems such as emulsions, lipsomes and 
nanosuspensions. However, its application is limited to liquid formulations and cannot be 
applied to dry powder. Polydispersity index (PDI) demonstrates the particle size 
distribution, values below 0.1 indicate that particles are homogeneous, values of 0.1 to 0.25 
show a narrow size distribution, while values above 0.5 mean a wide size distribution and 
usually unacceptable in  drug delivery systems {Patravale, 2004 #1161} .  
In terms of parenteral emulsion, the British Pharmacopoeia requires that the diameter 
of fat globules should not exceed 5μm {Wong, 2008 #429}. The USP Pharmacopeial 
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Forum has established the requirement and measurement methods. By using DLS method, 
the proposed intensity-weighted mean droplet diameter must be less than 500 nm, volume-
weighted percentage (based on light obscuration) of fat greater than 5μm should not exceed 
0.05% {Driscoll, 2006 #1192}. In the previous study, the physical stability of parenteral 
cyclosporine was generally evaluated visually for clarity, precipitate and color change. The 
use of particle size analysis will be more precise to detect the physical change during 
storage. For example, the compatibility of cyclosporine injection with fat emulsion 
injection has been studied by using DLS to measure emulsion size {Jacobson, 1993 #1174}.  
1.3.4 Development and validation HPLC stability-indicating method 
Typically, most stability-indicating methods are using HPLC. Method development 
and validation are mostly determined by intended purpose. For instance, selective stability 
method requires good resolution of API and each relevant impurity, while in specific 
method, it is unnecessary to separate each impurity. The general procedure (Figure  is 
described as below {Bakshi, 2002 #1149}: 
 
Method validation
Choice of method
Related substances Stress degradation  
Information
Drug Substance Drug Product
Other information (Packaging 
material, storage  condition)
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1.3.4.1 Get Information on drug, drug products, and potential degradation routes  
The knowledge of physicochemical properties of drug substance, excipients, and 
packaging materials is a good starting point for the stability-indicating method development. 
Degradation routes rely mostly on the structure of compound and preparation vehicles.  
 In new drug product development, degradation chemistry can be easily postulated 
from the existing related drugs, since the degradation behaviour of most new drugs are 
similar to their congeners. For example, penicillin in clinical practice has the same 
degradation behaviour as at the beta-lactam moiety {Bakshi, 2002 #1149}. Thus, 
degradation mechanisms of some old drugs are important assets in stability studies of new 
drugs. The properties such as pKa, logP, solubility, spectroscopy behaviour, drug 
degradants and potential impurities should be considered for the choice of method and 
method parameters. For example, the determination of stationary phase, mobile phase, 
sample extraction and preparation, and detector choice are all based on these properties of 
drugs, excipients, and degradants.   
1.3.4.2 Set up HPLC method and conduct stress degradation 
A short cut can be taken benefiting from existing methods. In the new drug product 
development activity, the existing method should be revalidated to be suitable in actual 
analysis, for the excipients and vehicles may influence or even alter the degradation 
pathways. In most cases, some modifications are necessary.  
Stress degradation should be designed based on the individual drug as well as drug 
products. The stress conditions are optimized based on trial and error. Normally, stress test 
is performed only on drug substance, because in most cases, it can provide sufficient 
potential degradants possibly present within the storage interval. However, in order to 
investigate the influence of excipients on degradation behaviour, drug products should also 
be subjected to stress degradation {Grimm, 1998 #1163}. Cyclosporine is a stable cyclic 
peptide; high temperature is usually required to get related degradants. In Kumar‟s study, 
the acid and base stress degradations for oral cyclosporine formulation were conducted at 
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80
o
C. The results showed that cyclosporine content did not change under base degradation, 
however, some degradant were generated from acid degradation  {Kumar, 2001 #1017}.   
1.3.4.3 Validation of stability-indicating method 
To validate a stability-indicating method, it is imperative to determine the validation 
parameters. For drug substance assays, detection limit is not critical. However, for 
impurities or degradants evaluation, low detection limits and quantitative limits should be 
determined.   
1.4 HPLC method validation 
Validation of an analytical method is to establish the process through the laboratory 
studies, in which the performance characteristics should meet the requirement for its 
intended use {Yuwono, 2005 #1164}. Reliability and reproducibility should be adequate 
for intended application. 
The fundamental attributes of validation include accuracy, precision, 
selectivity/specificity, detection limit, linearity and range. Validation can be classified as 
fully validated level and single-laboratory level. Generally, it is not always necessary to 
validate all parameters. The extent of validation depends on the intended use according to 
the corresponding regulations in FDA, ICH and USP Documents (Table 1.3). 
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Table 1.3 Parameters required for analytical method validation 
Reproduced from {Shabir, 2003 #1003;Yuwono, 2005 #1164;USP, 2004 #1165;Shabir, 
2003 #1003} 
Analytical Type Assay Impurity 
Quantitative testing 
Impurity 
Limit 
Performance 
characteristics 
Identification 
Accuracy USP Yes Yes * * No 
ICH Yes Yes No N/A No 
Precision USP Yes Yes No Yes No 
ICH N/A N/A N/A N/A N/A 
Repeatability USP N/A N/A N/A N/A N/A 
ICH Yes Yes No N/A No 
Intermediate 
precision 
USP N/A N/A N/A N/A N/A 
ICH Yes Yes No N/A No 
Specificity USP Yes Yes Yes * Yes 
ICH Yes Yes Yes N/A Yes 
LOD USP No No Yes * No 
ICH No No No N/A No 
LOQ USP No Yes No * No 
ICH No Yes No N/A No 
Linearity USP Yes Yes No * No 
ICH Yes Yes No N/A No 
Range USP Yes Yes * * No 
ICH Yes Yes No N/A No 
25 
 
“*” May be required, depending on the specific test; N/A: not available. 
Before validation, system suitability should be verified to ensure that 
chromatographic system is appropriate for the intended analysis. In general, acceptable 
parameters should be in a definite range. For instance, during the suitability test,  standards 
and assay samples should be stable within 2% deviation for 24 h {Shabir, 2003 #1003}. In 
most cases, change in retention time will impact on peak shape and thus lower result 
accuracy, so deviation of retention time should be as low as possible and the injection 
repeatability should be lower than 1%.  
Tailing factor TF stands for peak symmetry (Figure 1.5), it is calculated as: 
f
W
TF
2
05.0
      
where W0.05 is the width of the peak at 5% of height and f is the distance from the leading 
edge to peak maximum at a point 5% of the peak height {USP, 2011 #1004}. Figure 1.6 
represents a separation of two substances with respective retention times of tR1 and tR2, and 
widths of W1 and W2, Wh/2 is the width at half-height.  tM corresponds to the solvent front, 
implying the time required for unretained solvent elution. The resolution of two 
components in a mixture is calculated: 
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Figure 1.5 Tailing factor illustration  of HPLC 
Modified from {USP, 2011 #1004} 
Number of Theoretical Plates (N) indicates column efficiency. It is usually calculated 
as {USP, 2011 #1004}: 
2)/(16 WtN R  
Where tR ,W is retention time and peak width of analyte, respectively. 
The capacity factor (k), also known as retention factor, is defined as the ratio of 
substance mass dispersed in stationary phase (msp ) to that  in mobile phase (mmp): 
mp
sp
m
m
k 
 
It is determined as (Figure 1.6): 
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Figure 1.6 Chromatographic separation of two substances 
Modified from {USP, 2011 #1004} 
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The recommended parameters for the suitability test are {Shabir, 2003 #1003}: 
 Relative standard deviation (RSD) of repeated injections ≤ 1% ( n=5). 
 Tailing factor ≤ 2. 
 Resolution ≥2. 
 Theoretical plate ≥2000. 
 Capacity factor ≥2.   
Validation parameters are determined by the analytical purpose. For example, 
according to the regulation of USP and ICH, the quantitative assay of active ingredient 
requires validation of accuracy, precision, specificity, linearity, range. For the identification 
of impurities, the validation of accuracy, the limit of detection (LOD) and quantity (LOQ), 
repeatability, interim precision, linearity and range can be omitted.  
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1.4.1 Selectivity and specificity 
Selectivity and specificity are often interchangeably used. Specificity of analytical 
method refers to the ability to differentiate and quantify the analyte from other components 
such as degradation products, metabolites, impurities and matrix. Chromatography 
techniques require no interference between the analyte and other components. Normally, 
resolution of the analyte from other components should be more than 1.5-2 to ensure 
accuracy {Yuwono, 2005 #1164}. 
 However, compounds of similar structure are likely to coelute. In order to verify 
coeluted substances, peak purity should be verified. By using a HPLC system coupled with 
photo diode array (PDA) detector, UV-Vis spectrum at different wavelength can be 
recorded. Peak purity can be confirmed by comparing spectra from the upslope, apex and 
downslope, or the whole spectrum simulation {Papadoyannis, 2004 #1166}. 
Different terms are used to indicate peak purity. For example, match factor (MF) is 
used on Agilent system; similarity index is used on Shimadzu/LCsolution system. The 
principle is described in Figure 1.6  {Papadoyannis, 2004 #1166}. Let‟s assume that 
chromatogram A and B are response signals recorded at different wavelengths, in case of 
the pure peak, the ratio of the signals A and B (called ratiogram) will be constant and the 
ratiogram will be rectangular. For the first impure peak of coeluting analyses, due to 
different absorbance spectra and a slight difference in retention time, a significant distortion 
of rectangular form will take place. This is the basic principle of peak purity determination. 
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Figure 1.7 Signal ratiograms for impure and pure peaks at wavelength λ1 and  λ2.  
Modified from {Papadoyannis, 2004 #1166} 
 
Based on this principle, impurity as low as 0.5% of the analyte can be detected.  For 
instance, on Shimadzu/LCsolution system, if purity index is below 0.89, it is regarded as 
not pure, values of 0.90-0.95 indicate that the peak is contaminated. On HPLC without 
PDA detector, peak purity can be estimated by calculating tailing factor at different 
wavelengths. Peak purity can be assumed to be acceptable if tailing factors are identical at 
different wavelengths. However, when the impurity has very similar profile with analyte or 
has much lower concentration, other techniques LC-MS, GC-MS, LC-FTIR, LC-NMR 
should be used to verify the peak purity {Velagaleti, 2007 #1148}. 
If isolated impurities are available, the specificity can be determined simply by 
comparing the standard with the results from the samples consisting impurities, degradation 
products, and placebo ingredients. Normally, it is difficult to obtain and isolate all potential 
impurities and degradation products. Thus stress degradation is necessary to demonstrate 
stability-indicating power. Specificity can be evaluated by comparing chromatograms of 
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original products and degraded samples. Mostly, degradants and impurities do not need to 
be separated from each other, but need to be adequately resolved from the drug substance 
peak.  
1.4.2 Accuracy 
Accuracy of an analytical method is defined as the extent by which the value 
measured deviates from the true value {Yuwono, 2005 #1164}. There are several 
approaches to estimate accuracy. The first one is to compare the value obtained in a new 
method with a value known to be accurate. The second method is to add known 
concentrations to the sample and then compare the results with the true value. The third 
method is based on the calculation of recovery of standard or known analyte spiked into 
blank matrices or products. For the samples spiked into blank matrices, it is recommended 
that 5 analyte concentrations, covering the range 75% to 125% or 80%-120% of the target 
concentration. For the standard addition methods, the spiking concentration is in the range 
of 50-150% of the target concentration. Accuracy is assessed as percent recovery. The 
acceptance criterion is set depending on the analyte concentrations, recovery rate 98%-102% 
or 95%-105% can be acceptable for drug preparations. In biological analysis, recovery of  
90% -110% can be acceptable {Velagaleti, 2007 #1148}. 
1.4.3 Precision 
Precision of an analytical method expresses the closeness of agreement between 
several results. It is usually evaluated at three categories: repeatability, intermediate 
precision and reproducibility. Repeatability is the intraday precision. It is determined by 
one analyst using one equipment in one laboratory. According to ICH guidelines, nine 
determinations covering the specified range (for example, three concentrations 80%, 100%, 
120% of the target concentration, each sample is injected in triplicate) or six determinations 
at 100% of the target concentrations are required. Intermediate precision is evaluated based 
on the interday variation over a number of days or weeks, at least six determinations of 
three concentrations at three different times. Reproducibility is performed to assess the 
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precision between laboratories. These characteristics are essential for method transfer 
between laboratories.  
The criterion of relative standard deviation (RSD) depends on the nature of analysis 
study. For a finished drug product assay and content uniformity, RSD should be below 2% 
(intraday precision for 6 injections. n = 6) or 3% (intermediate precision for at least 6 
measurements. n ≥ 6). For the dissolution test, the acceptance criterion of repeatability is 
set as ≤ 3%, for bioanalytical study, it should not be more than 15% {Brodie, 2002 
#1167;Yuwono, 2005 #1164}.  
1.4.4 Limit of detection (LOD) and quantification (LOQ) 
LOD is defined as the lowest quantity at which the substance can be detected under 
the analytical condition. At LOD, analyte can be identified but not be quantitatively 
assayed. LOQ is the lowest quantity that can be determined with acceptable accuracy and 
precision. In chromatography, The LOD can be determined by the signal-to-noise ratio 
about 2:1 to 3:1. LOQ is estimated with the ratio of 10:1. The alternative estimation is 
based on the calibration standards. LOD and LOQ  are determined as follows {Chan, 2010 
#1168}: 
LOD = 3 σ/S 
LOQ = 10 σ/S 
Where σ is standard deviation of intercept, S is the slope of the calibration curve. In some 
case, this method need to be verified by measuring several samples near LOD or LOQ. 
Spectra comparison of  sample, placebo and matrix is needed to eliminate noise. LOQ can 
also be obtained by diluting known concentration of analytes until RSD of multiple 
injections is larger  than 2% {Yuwono, 2005 #1164}. 
1.4.5 Linearity 
Linearity of a method is defined as that the response directly obtained or after 
mathematical transformation is proportional to the concentration of the analyte. Either peak 
area or peak height can be used for calibration curve calculation, depending on the error 
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produced. Usually, the use of peak area is preferred to height, for peak area is directly 
related to concentration, while peak height varies depending on the retention time and 
overloading analyses {Yuwono, 2005 #1164}. Linearity can be determined by measuring 
the signal of a series of concentrations. According to ICH, at least five concentrations over 
the entire working range are required. Standard samples can be prepared by weighing 
different amounts of standards or diluting standard stock solutions. The latter approach is 
popular and suitable in case of low concentration preparation, in which weighing error 
would be much higher. Linearity is produced by calculating the regression line using 
mathematical methods such as least mean squares. Linearity is confirmed by determination 
coefficient of linear regression. In most cases, more than 0.997 is acceptable {Chan, 2010 
#1168}. Otherwise, further statistic analysis is required {Yuwono, 2005 #1164}. Based on 
ICH regulations, the slope, residual sum of squares, and intercept should be reported {ICH, 
2005`, Nov. #1169}.  
1.4.6 Range 
In USP 34, the analytical method range refers to the interval between upper and lower 
levels of the analyse that has been demonstrated to have an acceptable level of precision, 
accuracy, and linearity. Normally, for the assay of drugs or drug products, the range should 
cover 80% to 120% of target concentrations. For content uniformity, it should be between 
70-130%. While for controlled release products, the range should cover 0-110% of the label 
claim {Yuwono, 2005 #1164;Chan, 2010 #1168}. 
1.4.7 Robustness and ruggedness 
Robustness of an analytical method is defined as the ability to remain unaffected by 
small, but deliberate variations in method parameters. For HPLC method development, the 
parameters required to be tested include flow rate, column temperature, column origin, 
injection volume, mobile phase composition, the pH of buffer and detection wavelength 
{Ermer, 2001 #1170}. Ruggedness is determined by following the same procedure by 
different analysts in different laboratories under slightly different conditions.  
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In conclusion, validation of HPLC method ensures that the characteristics meet the 
regulated guidelines for intended analysis. So the validation should be carried out before 
the routine analysis. The requirement of validation parameters and level depends on the 
intended purpose and choice of method.  
1.5 Cyclosporine stability-indicating methods and stability study 
Several analytical methods for cyclosporine have been reported. In brief, these 
methods include reverse phase HPLC employing acetronitrile- or tetrahydrofuran-based 
mobile phases. The United States Pharmacopeia (USP) method employed reverse phase 
column C18 as stationary phase, and acetonitrile based mixture as mobile phase {USP34-
NF29, 2011c #1005}. A similar method has been developed for oral cyclosporine stability 
evaluation, in which  Nuclosil RP-2 column was used as stationary phase,  a mixture of 
acetonitrile, water and phosphoric acid was used as mobile phase. This method was 
demonstrated to be stability-indicating by stress degradation tests {Kumar, 2001 #1017}.  
Another method using  mobile phase of  68% (v/v) acetonitrile in water has also been 
reported for the compatibility of plastic syringe with oral cyclosporine {Ptachcinski, 1986 
#1171}. 
  In another report, Bonifacioa et al developed an HPLC method using Lichrospher 
RP-18 column and a mixture of tetrahydrofuran (THF) and aqueous phosphoric acid 
(0.05M in water) (44:56) as mobile phase {Bonifacio, 2009 #1011}. The main degradants 
and related substances including ID-005-95, cyclosporine H, isocyclosporin H, and 
potential impurities isocyclosporin A, Cyclosporin B and Cyclosporin G in oral 
formulations, could be resolved and determined simultaneously. This method can provide 
more stability information than other reported methods. It accurately measured 
cyclosporine concentration in oral dosage. However, high proportion of THF in mobile 
phase may attack polyetheretherketone polymer (PEEK) tubing employed in most modern 
HPLC systems, thus the application is restricted only to the system compatible with THF 
solvents  {Clayton McNeff, 2011 #1006}.  
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Approximately 70% of world‟s supply of acetonitrile was consumed in 
pharmaceutical industry as the solvent. The prices of HPLC-grade acetonitrile has been 
increasing rapidly because of worldwide shortage.  Laboratories are under pressure to re-
develop HPLC methods by use alternate solvents such as methanol or long chain alcohols 
{Ankur M. Desai , 2011 #1195;Ankur M. Desai , 2011 #1195}. From an environmental 
perspective, methanol is preferable solvent than the use of acetonitrile and tetrahydrofuran 
{Christian C, 2007 #1196}. Thus, in this study, methanol-based HPLC method will be 
developed and validated.  
The compatibility of various containers with cyclosporine has been studied. The 
study on stability of oral cyclosporine liquid (Sandimmune® Oral, Sandoz) stored in 
syringes showed that cyclosporine remained stable for 28 days at 25°C. there is no stability 
data of intravenous cyclosporine in syringe. Stability of intravenous cyclosporine 
(Sandimmune® I.V., Sandoz) in PVC tubes and containers has been extensively studied. A 
significant amount of drug can be lost due to sorption on PVC surface. The extent of drug 
loss depended on the concentration, the vehicle and the container {Ptachcinski, 1986 
#1127;Shea, 1989 #1173}. In addition, phthalate is leached from PVC containers due to the 
existence of polyoxyethyleted castor oil in formulation.   
1.6 Hypothesis of the thesis 
A stability-indicating HPLC methods have been reported using acetonitrile or 
tetrahydrofuran (THF) mobile phases. THF based mobile phase (THF 44%) is incompatible 
with PEEK tubing in some HPLC systems. Also, acetonitrile and tetrahydrofuran are more 
costly and environmental unfavourable. Therefore, there is a need to develop a methanol-
water HPLC stability indicating method.  
 Cyclosporine has a narrow therapeutic window index {Shaw, 1999 #1119;Armstrong, 
2001 #1118}, the administration requires consistent concentrations during infusion, thus 
stability study and compatibility in infusion containers are necessary. Glass containers have 
been superseded by plastic bags. PVC bags are restricted due to DEHP leaching. Recently, 
non-PVC containers are alternative for intravenous cyclosporine preparations. Plastic 
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syringes are commonly used for paediatric patients. Plastic syringes usually consist of 
rubber plunger. Up to now, no stability data on these non-PVC containers are available in 
literature, the study on compatibility of these containers with intravenous cyclosporine is 
important to ensure safety administration.  
1.7 Objectives of the thesis 
This study is to develop a cost-effective and environmental favourable HPLC method 
for stability study and routine assays of intravenous cyclosporine. The specific aims of this 
project are: 
 Evaluate the stability of intravenous cyclosporine preparations stored in polypropylene-
polyolefin (PP-PO) bags (Baxter Corp., Mississauga, Ontario, Canada). 
 Evaluate the stability of intravenous cyclosporine preparations stored in polypropylene 
(PP) syringes (60 mL, Luer-Lok, Becton-Dickinson, Mississauga, Ontario, Canada). 
 Evaluate the suitability of polypropylene (PP) syringes (1 mL, 5 mL Luer-Lok, Becton-
Dickinson, Mississauga, Ontario, Canada) for sampling and transferring intravenous 
cyclosporine. 
 Assess the stability of intravenous cyclosporine preparations stored in ethylene vinyl 
acetate (EVA) bags (250 mL, Baxa).  
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Chapter two 
2 Development and validation of a stability-indicating 
HPLC method for intravenous cyclosporine assay 
2.1 Introduction 
Several analytical and bioanalytical method for cyclosporine assays have been 
developed (cf 1.5 in Chapter one). Acetonitrile-based HPLC methods are generally 
recommended in USP. {USP34-NF29, 2011c #1005}. A tetrahydrofuran-based HPLC 
method can simultaneously quantify cyclosporine and possible impurities in oral 
formulations {Bonifacio, 2009 #1011}. In this section, a methanol-based HPLC is 
developed for routine assay in hospital and stability study of intravenous cyclosporine.  
Based on the properties of cyclosporine and the nature of intravenous formulation, 
stress degradation of cyclosporine and injection products will be performed to study the 
stability-indicating properties of the HPLC method. Furthermore, suitability of the 
chromatographic system including repeatability and column efficiency will be evaluated 
according to ICH and USP guidelines. Performance parameters such as specificity, 
accuracy, precision, linearity, detection limit and robustness will also be validated. 
2.2 Materials and method 
2.2.1 Materials 
All reagents used in the experiments were analytical grade. The deionised water (18.2 
MΩ) used for HPLC and sample preparation was generated with a Millipore Milli-Q 
system (Bedford, MA). Methanol (HPLC grade) was purchased from JT Baker 
(Phillipsburg, NJ). Phosphoric acid (A.C.S., 85%) and hydrogen chloride (A.C.S., 37%) 
were supplied by Fisher Scientific Canada. Triethylamine (A.C.S.) was obtained from 
Laboratoire MAT Inc. Nylon membrane filter (Nylaflo
TM  
0.45 µm) for mobile phase 
filtration and syringe filter (Supor ○R  (PES 0.2 µm) was obtained from Pall, Life Sciences. 
Cyclosporine (98%, lot H890) was purchased from AK Scientific Inc. and used as reference 
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standard. Sandimmune® I.V. (50 mg/mL, lot S0034, exp FEB2012 and lot S0040, exp 
MAR2013) were obtained from Novartis, Canada.  Dextrose injection 5% (D5W, Lot 
W9H18B0) and sodium chloride injection 0.9% (NS, Lot W9I14M0) were supplied by 
Baxter Corporation, Canada.   
2.2.2 HPLC system  
A Prominence UFLC system (Shimadzu Corporation, Kyoto, Japan) consisting of a 
vacuum degasser (DGU-20), an autosampler (SIL-20AC), a quaternary-flow solvent-
delivery system (LC-20AD), a column oven (CTO-20AC), a diode-array detector (SPD-
M20A) and the LC Solution software (version 1.21) was used. Separation was performed 
on a column C18 (Zorbax, SB-C18, 4.6×250 mm) coupled with security guard cartridge 
(Phenomenex, C18, ODS, 3.0×4 mm). The isocratic mobile phase consisted of a mixture of 
HPLC-grade methanol and water (86:14, V/V) at a flow rate of 1mL/min. Column 
temperature was controlled at 50°C.  Quantification was performed by integration of the 
area at a detection wavelength of 203 nm.  
2.2.3 Sample preparation and HPLC assay 
2.2.3.1 Preparation of  standards 
The stock standard solution was prepared by dissolving cyclosporine powder (about 
40 mg) with methanol in a 10 mL volumetric flask. Seven calibration standard solutions 
were prepared by diluting with methanol to obtain concentrations in the range of 0.05 to 
0.40 mg/mL. Standards were assayed by HPLC with injection volumes of 20 µL.  Another 
calibration curve was similarly prepared using seven solutions of concentrations varying 
between 0.50 and 4.0 mg/mL, and assayed on HPLC with injection volumes of 2 µL.  
2.2.3.2 Preparation of samples for precision evaluation 
 Intravenous cyclosporine injections (0.2 and 2.5 mg/mL) were aseptically prepared 
by diluting Sandimmune® I.V. 50 mg/mL with 5% dextrose or 0.9% sodium chloride. The 
samples were filled in glass vials and stored in refrigerator (2-8 
o
C) as controls. The 
samples of 0.2 mg/mL and 2.5 mg/mL were injected with volumes of 20 µL and 2 µL, 
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respectively. Each sample was injected in duplicate. Intraday precision was evaluated by 
calculating relative deviation of 5 injections. Interday  precision was evaluated based on the 
results at 5 time points during 1 week.  
2.2.3.3 Preparation of samples for accuracy evaluation  
Accuracy was evaluated by spiking standard cyclosporine with Sandimmune® I.V.  
Intravenous cyclosporine injection was prepared by diluting Sandimmune® I.V. with 
methanol to the concentration 0.207 mg/mL. A series of spiked solutions were prepared in 
triplicate by mixing them with standard solution (0.181 mg/mL) at the ratio (V/V) of 75:25, 
50:50, 25:75.  Each sample was assayed in triplicate with injection volume 20 µL.  
2.2.3.4 Generation of degradation products  
A degradation sample was prepared by adding about 13 mg (98%) of cyclosporine 
powder to hydrochloric acid (12.5 mL, 1 N). After refluxing at 80°C for 4 h, the solution 
was neutralized with sodium hydroxide (1 N) to pH 6.8, diluted with methanol to about 
0.25 mg/mL and filtered with 0.2 µm membrane. The final sample was assayed by HPLC 
with injection volume of 20 µL {Kumar, 2001 #1017}. Similarly, stress degradation testing 
was conducted on Sandimmune
®
 I.V. (Novartis) to rule out interference with the excipients. 
The test sample was prepared by adding Sandimmune
®
 I.V. solution (0.25 mL) to 
hydrochloric acid (12.5 mL, 1 N) followed by the same procedure as described above. In 
order to investigate the influence of temperature on degradation and to obtain stability 
related degradation products, 13.00 mg of standard cyclosporine was mixed with 
hydrochloric acid (2 mL, 1 N) and kept at room temperature for 5 days without protection 
from light and similarly assayed.  
2.3 Results and discussion 
2.3.1 Method development 
The current RP-HPLC method used a C18 column as stationary phase. The mobile 
phase composition was optimized to achieve an adequate resolution of cyclosporine from 
the impurity peak. The ratio of methanol and water is determined as 86:14 (V/V). It has 
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been reported that on acetonitrie-water based HPLC, chromatogram of cyclosporine was 
significantly influenced by column temperature {Nishikawa, 1994 #16016}. The peak 
became broadening and tailing as temperature decreased from 60
 o
C to 20 
o
C. Such 
behaviour was accounted for as the inter-conversion between multiple conformations. 
Higher temperature facilitated one conformation and a faster equilibrium, thus good 
performance was achieved with higher separation efficiency. Considering the boiling point 
of methanol, the column temperature was controlled  at 50 
o
C. Cyclosporine has UV 
absorption at 190-210 nm {Hossan, 1987 #1100}, based on the absorption profile detected 
by PDA,  the integration area was performed at 203 nm.   
2.3.2 Validation of the HPLC method 
2.3.2.1 System suitability 
System suitability was evaluated by injecting standard solutions. The solution of 
Sandimmune in D5W was injected to estimate the resolution from the excipient in 
intravenous dosage. The suitability parameters are shown in Table 2.1.  The USP method 
requires that the number of theoretical plates should not be less than 700 (USP34-NF29 
2011). The lower column efficiency can be attributed to broadening cyclosporine peak, 
which turns out to be a challenge in RP-HPLC assay (Nishikawa, Hasumi et al. 1994). 
Even though the ICH recommends using columns with theoretical plates N > 2000 in 
HPLC analysis, in some cases, this criterion is validated if the precision and accuracy can 
meet the requirement (Épshtein 2004).  
An important suitability parameter was resolution. By comparing chromatogram of 
intravenous cyclosporine to standard, new peaks were observed resulting from Cremophor 
EL. However, they did not interfere with cyclosporine (Figure 2.1). The resolution was 3.92 
from cyclosporine. Tailing factor indicates peak asymmetry. It is critical to the accuracy of 
area integration, since the determination of end time becomes difficult with increasing 
tailing factor. Both ICH and USP specifications require that the tailing factor be less than 2. 
In the current method, the tailing factor was 1.052 and ensured accurate results in stability 
study {Kumar, 2001 #1017;Shabir, 2003 #1003}.  
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Table 2.1 HPLC System suitability parameters 
 RSD  of 
retention 
time % 
RSD  of 
peak area 
Number of 
theoretical plates 
Tailing 
factor 
Resolution 
Current HPLC 
method 
0.99% 0.37% 1309 ± 10 1.052 ± 
0.004 
3.92 
ICH 
specification 
< 1 % < 2 % > 2000 < 2 > 1 
USP 
specification 
< 2 % < 2 % > 700
a 
< 2 > 1 
a
 Theoretical plate number required for cyclosporine assay  
 
Figure 2.1 Overlay of chromatograms of  D5W injection, NS injection, cyclosporine,  
Sandimmune I.V, Cyclosporine after degradation (1 N HCl at 80°C for 4 h) and 
Sandimmune I.V. after  degradation (1 N HCl at 80°C for 4 h). 
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2.3.2.2 Specificity 
In order to validate the specificity of the method, cyclosporine should be resolved 
from possible degradants or other potential impurities. Based on the results of stress 
degradation tests under acid, alkali, hydrogen peroxide, heat or light exposure {Kumar, 
2001 #1017}, the main degradation products, such as isocyclosporine, may be produced 
after acidic treatment. Thus, in this study, the stress degradation was only performed by 
subjecting cyclosporine or Sandimmune
®
 I.V. to HCl at 80°C for 4 h. The percent of 
degradation of standard cyclosporine was about 8.9% based on HPLC assays, indicating it 
was sufficient to provide related degradants. The overlay of chromatograms is shown in 
Figure 2.1. No interference occurred with cyclosporine after acidic degradation. The 
cyclosporine peak (retention time 8.9 min) purity was determined by PDA detector in the 
range of 190 nm to 600 nm, the purity index value is higher than 0.999, showing no 
significant impurity coeluted with cyclosporine. By comparing the chromatograms profiles 
of cyclosporine before and after degradation, no significant change was observed. The 
possible degradation product isocyclosporine is ionisable, thus it might elute much faster 
than cyclosporine. Considering the oligopeptide structure of cyclosporine, and the storage 
condition at room temperature, degradation was also conducted at room temperature for 5 
days, cyclosporine peak purity was 0.999, showing that there was still no peak interference 
with cyclosporine.  
Due to PDA limitations for detecting coeluting substances with very low  
concentrations or very similar spectra {Papadoyannis, 2004 #1166}, mobile phases with 
different pH values were used to verify if any degradants coeluted with cyclosporine. 
Alteration of pH in mobile phase is possible to discriminate the substances of similar 
structures. Three types of mobile phases: a mixture of methanol and water (86:14, V/V), a 
mixture of methanol, water and phosphoric acid (86:14:0.1, V/V, pH 3.1) and a mixture of  
methanol, water and triethylamine  (86:14:0.1, V/V, pH 9.25)  were delivered in another 
HPLC system (Shimadzu HPLC system: consisting of LC-20AT pump, DGU-20 degasser, 
SIL-20A HT autosampler, SPD-20A UV detector, CTO-20AC column oven and Shimadzu 
Lcsolution software). The retention time of cyclosporine was 12.5min, 12.8min, 20.3min, 
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respectively when using different mobile phases (Figure 2.2, 2.3, 2.4). No interfering peak 
occurred with cyclosporine. In conclusion, both PDA purity determination and HPLC 
chromatograms achieved by using different mobile phases confirmed no compound 
coeluted with cyclosporine.  
 
Figure 2.2 Chromatograms of standard cyclosporine (a) and degraded sample (b)  
Mobile phase: methanol:water 86:14 (V/V). 
 
 
Figure 2.3 Chromatograms of standard cyclosporine (a) and degraded sample (b)  
Mobile phase: methanol: water: phosphoric acid 86:14:0.1 (V/V, pH 3.1). 
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Figure 2.4 Chromatograms of standard cyclosporine (a) and degraded sample (b)  
Mobile phase: methanol: water : triethylamine = 60:10:0.07 (V/V, pH 9.25). 
Regarding stress degradation of intravenous cyclosporine, some new peaks with 
retention times of 5.3 min and 12.7 min appeared ( Figure 2.1). However, those peaks did 
not interfere with cyclosporine peak. It was assumed that these new peaks were generated 
from degradation of Cremophor EL present in the formulation.  
Based on the above discussion, the current methanol-based HPLC method was 
demonstrated stability-indicating.  
2.3.2.3 Linearity and range 
Calibration standard were prepared in the range of 0.05 mg/mL to 0.40 mg/mL. Peak 
area of each standard (injection volume of 20 µL) versus concentration was plotted. Good 
linearity was obtained with regression coefficient 0.99996. As the  target concentrations 
was 0.2 mg/mL and 2.5 mg/mL in the current stability study, to eliminate the measurement 
error caused by diluting,  another calibration curve was prepared in the range of 0.50-4.0 
mg/mL with injection volume of 2 µL. As shown in Table 2.2, the linear regression 
coefficient was 0.99999 (Figure 2.5).  
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Table 2.2 Linearity regression results 
Calibration range 
CyA mg/mL 
Injection 
volume (µL) 
Slope 
(Au mL/mg) 
Intercept 
(Au) 
R
2
 
 
0.05 - 0.40 
 
20 
 
(5.09±0.014)×10
7
 
 
(1.02±0.25) ×10
5
 
 
0.99996 
 
0.50 - 4.0 
 
2 
 
(5.02±0.008) ×10
5
 
 
(1.69±0.91) ×10
4
 
 
0.99999 
 
 
 
 
 
 
 
 
 
 
Figure 2.5 Standard curve of cyclosporine: peak area versus amount of cyclosporine 
injected. 
 
The area was plotted against the amount of cyclosporine injected. As shown in 
Figure 2.5, the linearity of the two standard curves was similar to each other, illustrating 
quantification of concentrated sample 2.5 mg/mL can be performed by simply reducing 
injection volume. 
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The linear range of calibration curves covered 80% to 120% of the target 
concentrations 0.2 mg/mL and 2.5 mg/mL, satisfying the USP and ICH regulations. 
2.3.2.4 Detection Limit 
Based on the calibration curve, the limit of detection (LOD) and quantification (LOQ) 
were calculated as {Chan, 2010 #1168}: 
LOD = 3 σ/S 
LOQ = 10 σ/S 
Where σ is standard deviation of intercept, S is the slope of the calibration curve 
(Table 2.2). The calculated LOD and LOQ were 1.47 ×10
-3 
mg/mL and 4.91 ×10
-3 
mg/mL, 
respectively. As the current study did not require the quantification of impurities, no extra 
experiment was performed involving the impurities or related substances. 
2.3.2.5 Precision  
 
Table 2.3 Intraday and interday precision 
a
 
Sample Cya concentration 
mg/mL 
solvent Intraday 
RSD 
Interday 
RSD 
Standard 
 
0.247  methanol 0.32%(n=5) 0.33% (n=6) 
Sandimmune I.V. 0.2  D5W  0.12%  (n=5) 
Sandimmune I.V. 0.2  NS  0.36%  (n=5) 
Sandimmune I.V. 2.5  D5W  0.57%  (n=5) 
Sandimmune I.V. 2.5 NS  0.12%  (n=5) 
a  All samples were stored in glass vials and refrigerated (2-8 
o
C).  
Precision in this method was evaluated with respect to intraday and interday 
repeatability. It was expressed as percent of relative standard deviation (RSD). The intraday 
repeatability was calculated from five replicate injections of standard cyclosporine solution 
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0.247 mg/mL. As shown in Table 2.3, the RSD was 0.32%, meeting the USP and ICH 
specification (< 2%).  Interday precision was evaluated on the solutions relevant to stability 
test, including standard solution, the intravenous cyclosporine preparations at 0.2 mg/mL 
and 2.5 mg/mL concentration levels.  All the RSD values were below 1%, illustrating good 
reproducibility of this method. 
2.3.2.6 Accuracy  
The accuracy of the method was assessed by standard addition. In order to verify if 
the possible uncertainty of product composition affects the quantification, a placebo (matrix) 
was spiked with known quantities of cyclosporine {Épshtein, 2004 #16019}. The placebo 
for intravenous cyclosporine injection consisted of all the excipients in Sandimmune I.V. 
and the diluents D5W or NS injections. In our previous studies on intravenous cyclosporine 
assay, it was found that the diluents: methanol, NS and D5W did not influence the 
quantification of Sandimmune I.V. In the specificity study (Figure 2.1), there was good 
baseline and no peak was observed in chromatograms of NS and D5W. Thus, these diluents 
have no impact on cyclosporine determination.   
Table 2.4 Accuracy results 
a
 
Spiking Sample Volume  fraction of 
Sandimmune solution added  
(0.207 mg/mL in methanol) 
 
Volume fraction of standard 
added (0.181 mg/mL in 
methanol) 
 
Recovery  % 
a
 
1 75% 25% 99.80±1.04 
2 50% 50% 99.92±0.55 
3 25% 75% 100.1±0.28 
a. Average of 9 determinations. (Each sample was prepared in triplicate and assayed with three injections). 
Furthermore, the low solubility of cyclosporine in D5W or NS did not allow the 
preparation of cyclosporine solutions in these vehicles. Therefore, the spiking solutions 
were prepared by dissolving both cyclosporine powder and intravenous cyclosporine 
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(Sandimmune I.V.) in methanol instead of injection diluents, and then mixed at three 
concentration levels in the linear range.  The recovered standard cyclosporine was 
calculated to represent the accuracy:  
𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑦  % =
𝑇ℎ𝑒 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑐𝑎𝑙𝑐𝑢𝑙𝑎𝑡𝑒𝑑
𝑇ℎ𝑒 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑎𝑑𝑑𝑒𝑑
× 100% 
Assuming that the concentrations of Sandimmune and standard are C1 and C2, 
respectively, the measured concentration of spiking mixture is C, the volume fractions of 
Sandimmune and standard are F1 and  F2, respectively,  the recovery rate can be calculated 
as: 
𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑦  % =
𝐶 − 𝐶1  × 𝐹1
𝐶2 × 𝐹2
× 100% 
Generally, the acceptance criterion for recovery data is 98-102% for drug 
preparations {Velagaleti, 2007 #1148}, in the current method, the recovery rate was 
between 99.80% to 100.1% (Table 2.4), indicating good accuracy can be obtained in this 
method.  
2.3.2.7 Robustness 
The parameters for robustness assessment should include flow rate, column 
temperature, mobile phase composition, buffer pH, column supplier and detection 
wavelength {Ermer, 2001 #1170}. Considering  that the method  used a reverse phase 
column and  isocratic mobile phase of methanol and water, robustness was assessed under 
various conditions, including temperature at  three different temperatures (45 
o
 C,  50
 o
 C,  
55 
o
 C),  flow rate at 0.8 mL/min,  1.0  mL/min, 1.2 mL/min. The effect of mobile phase 
composition was also investigated. The ratio of methanol to water varied slightly from   84: 
16 to 88:12 (V/V). The robustness results are illustrated in Error! Reference source not found..  
The system suitability was primarily indicated by RSD of retention time (RT) and peak area, 
as well as the resolution values. At each condition, RSD % is less than 1%; the resolution is 
more than 2, confirming that the system was robust and could applied to the stability assay 
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if a minor change in instrument parameters. However, the results indicated that retention 
time was significantly influenced by mobile phase composition and column temperature. 
Low temperature caused peak broadening and significantly affected the separation 
efficiency; the number of theoretical plates decreased from 1242 to 824 when performing at 
low temperature. It means that the temperature and mobile phase composition should be 
highlighted to ensure good reproducibility when transferring method.  
Table 2.5 Robustness with variation of flow rate, column temperature 
and mobile phase 
a
 
 
Parameter Variable 
parameter 
RT 
min 
RT 
RSD% 
Peak 
area 
RSD% 
Tailing 
factor 
Theoritical 
plates 
number 
Resolution 
 Normal
b 
9.21±0.005 0.06 0.15 1.155±0.003 1242±5 3.75±0.16 
Flow rate 
(mL/min) 
0.9 10.26±0.003 0.03 0.27 1.158±0.002 1360±7 3.78±0.08 
1.1 8.30±0.002 0.02 0.19 1.157±0.002 1163±2 3.04±0.54 
Temperature 
(
o
C) 
45 9.84±0.005 0.05 0.34 1.130±0.004 824±7 3.58±0.33 
55 8.60±0.003 0.04 0.19 1.194±0.002 1796±2 3.87±0.12 
Mobile phase 
methanol:water 
(V/V) 
84:16 12.13±0.005 0.04 0.08 1.131±0.004 1273±14 3.98±0.71 
88:12 7.33±0.006 0.08 0.53 1.183±0.003 1283±8 3.15±0.13 
a. RSD% is calculated based on the results of triplicate injections.  
b. Normal conditions are under 50o C, 1.0 mL/min, methanol: water 86:14 (V/V). 
 
2.4 Conclusion 
Based on the discussion above, a new HPLC method, using C18 column and 
methanol-water as mobile phase, was successfully developed. The validation parameters 
indicated it was stability-indicating and could be applied to the stability study of 
intravenous cyclosporine.   
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3.1 Abstract 
Purpose: the stability of cyclosporine diluted to 0.2 or 2.5 mg/mL with 0.9% sodium 
chloride injection or 5% dextrose injection and stored in polypropylene-polyolefin 
containers or polypropylene syringes was evaluated. Methods: intravenous cyclosporine 
solutions (0.2 and 2.5 mg/mL) were aseptically prepared and transferred to 250-mL 
polypropylene-polyolefin bags or 60-mL polypropylene syringes. Chemical stability was 
measured using a stability-indicating high-performance liquid chromatography (HPLC) 
assay. Physical stability was assessed by visual inspection and a dynamic light scattering 
(DLS) method. Results: after 14 days, HPLC assay showed that the samples of I.V. 
cyclosporine stored in polypropylene–polyolefin bags remained chemically stable (> 98% 
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of initial amount remaining); the physical stability of the samples was confirmed by DLS 
and visual inspection. The samples stored in polypropylene syringes were found to contain 
an impurity (attributed to leaching of a syringe component by the solution) that could be 
detected by HPLC after 1 day; on further investigation, no leaching was detected when the 
syringes were exposed to undiluted I.V. cyclosporine 50 mg/mL for 10 minutes. 
Conclusion: samples of I.V. cyclosporine solutions of 0.2 and 2.5 mg/mL diluted in 0.9% 
sodium chloride injection or 5% dextrose injection and stored at 25 °C in polypropylene-
polyolefin bags were physically and chemically stable for at least 14 days. When stored in 
polypropylene syringes, the samples were contaminated by an impurity within 1 day; 
however, the short-term (i.e., ≤10 minutes) use of the syringes for the preparation and 
transfer of I.V. cyclosporine solution is considered safe. 
Index terms: Chromatography, liquid; Concentration; Containers; Contamination; 
Cyclosporine; Dextrose; Diluents; Immunosuppressive agents; Injections; Polyolefin; 
Polypropylene; Sodium chloride; Stability; Storage; Syringes  
3.2 Introduction   
Cyclosporine is a potent immunosuppressive agent with a narrow therapeutic range. 
It strongly suppresses cell-mediated immunity and is used to prolong the survival of 
allogenic transplants and for the treatment of various autoimmune diseases {Novartis, 2011 
#1113}. 
Parenteral preparations contain cyclosporine (50 mg/mL), alcohol (278 mg/mL), and 
polyoxyethylated castor oil (650 mg/mL). Once diluted, I.V. preparations produce a 
dispersed system of cyclosporine in polyoxylated castor oil micelles. According to the 
manufacturer‟s product monograph, this preparation must be diluted with 0.9% sodium 
chloride injection or 5% dextrose injection at a ratio of 1:20 to 1:100 immediately before 
administration {Novartis, 2011 #1113}.
 
 Phthalate stripping by the polyoxyethylated castor 
oil from plasticized polyvinyl chloride (PVC) containers is a known problem; therefore, 
these containers cannot be recommended, and glass containers must be used whenever 
possible. Furthermore, containers and stoppers should be free of silicone oil and fatty 
substances {Novartis, 2011 #1113}. 
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Because the 250-mL glass containers of 5% dextrose have been discontinued, other 
alternatives for preparation of I.V. cyclosporine are required. A literature search found no 
useful data on the stability of I.V. cyclosporine solutions prepared in non-PVC containers 
other than glass. This study was conducted to provide data on the stability of I.V. 
cyclosporine in polypropylene-polyolefin containers. Also, since most hospital pharmacies 
prepare I.V. medications in a syringe format, the stability of I.V. cyclosporine in 
polypropylene syringes was tested.  
Cyclosporine is a highly lipophilic (log P 2.92) and noncharged cyclic peptide of 11 
amino acid residues {Wishart DS, 2008 #1197;Wishart DS, 2006 #1198}. Its solubility in 
water is as low as 0.04 mg/mL at 25 °C {Muller, 2006 #1179}. Furthermore, cyclosporine 
is a very stable molecule. Degradation of the cyclosporine molecule has been investigated 
under several stress conditions {Hassan MM, 1987 #1199;Bonifacio, 2009 #1011;Kumar, 
2001 #1017}, and up to five known degradation products have been reported; however, 
significant degradation has been observed only under acidic conditions
 
 {Kumar, 2001 
#1017}. Several high-performance liquid chromatography (HPLC) methods have also been 
studied to validate cyclosporine‟s stability {Bonifacio, 2009 #1011;Kumar, 2001 
#1017;Jacobson, 1993 #1174;Ptachcinski, 1986 #1127;Shea, 1989 #1173}. All these 
methods are acetonitrile or tetrahydrofuran based. Due to cost and ecologic considerations, 
there is a need for the development of a methanol-based HPLC method.  
The stability of I.V. cyclosporine in PVC containers has been previously studied 
{Ptachcinski, 1986 #1127;Shea, 1989 #1173}. A significant amount of drug can be lost by 
adsorption to PVC, with the extent of drug loss depending on the concentration, the vehicle, 
and the container. It was reported that cyclosporine 2 mg/mL in 5% dextrose injection 
remained stable for 24 hours in PVC bags, while the stability of cyclosporine in 0.9% 
sodium chloride injection decreased after only 6 hours {Ptachcinski, 1986 #1127;Shea, 
1989 #1173} .  
In previous studies, the physical stability of cyclosporine was evaluated by visual 
inspection {Jacobson, 1993 #1174}. Due to the micellar nature of the cyclosporine I.V. 
preparation, dynamic light scattering (DLS) is the method of choice for evaluating physical 
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changes; DLS can measure the nanometer-scale micelles and allow the monitoring of 
physical stability over time. Combined with visual observation, this method can be used to 
investigate the physical stability of cyclosporine injection and detect changes that would 
otherwise not be visible.  
The objective of the study described here was to investigate the chemical and 
physical stability of cyclosporine in 5% dextrose injection and 0.9% sodium chloride 
injection stored in polypropylene syringes or polypropylene-polyolefin bags. 
3.3 Methods 
3.3.1 Sample preparation 
  Cyclosporine for injection (0.2 and 2.5 mg/mL) was aseptically prepared by diluting 
I.V. cyclosporine 
a
 with 0.9% sodium chloride 
b
 or 5% dextrose injection.
c
 The diluted 
preparations (60 mL) were then transferred in 60-mL polypropylene syringes
d
. Additional 
diluted solutions (100 mL) were prepared in empty polypropylene-polyolefin containers
e
. 
All samples were prepared in triplicate. Containers were stored at 25 ± 2 °C and sampled 
(1.4 mL) at time zero and after 3, 7, and 14 days. 
3.3.2 HPLC assay method 
  The optimized method to assay cyclosporine by HPLC was to use an ultrafast liquid 
chromatography system consisting of a vacuum degasser
f
 , an autosampler
g
 , a quaternary-
flow solvent-delivery system 
h
, a C18 column
i 
, a column oven
j 
, a diode-array detector
k
, 
and the LC Solution software (version 1.21, Shimadzu Corporation, Kyoto, Japan). The 
isocratic mobile phase consisted of a mixture of HPLC grade methanol and water (86:14, 
by volume) at a flow rate of 1 mL/min. The column was heated to 50 °C. Injection volumes 
of 20 and 2 µL were used for 0.2- and 2.5-mg/mL samples, respectively. The run time of 20 
min is set up for analysis. Quantitation was performed by integration of the area under the 
curve at a detection wavelength of 203 nm at a retention time of about 8.9 minutes.  
Each analysis was confirmed by a second injection, with an acceptance specification 
of < 1% of difference reported as the average of both analyses. Peak purity was also 
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confirmed by calculating the similarity index between 190 and 250 nm, with an acceptance 
specification of  > 99.99%. 
Seven calibration standard solutions were prepared by dissolving cyclosporine 
powder
l
 with HPLC-grade methanol to concentrations of 0.05–0.40 mg/mL. The standards 
were assayed by HPLC with injection volumes of 20 µL, and a seven-point calibration 
curve was obtained by linear regression (r
2
 = 0.9999). Another calibration curve was 
similarly prepared using seven solutions of concentrations of 0.5–4.0 mg/mL and an 
injection volume of 2 µL (r
2
 =0.9999). The calibration standards were prepared using pure 
methanol rather than a mixture of water, alcohol, and polyoxylated castor oil; this 
facilitated the complete dissolution of cyclosporine and also prevented any degradation 
during the preparation of the calibration samples. 
The precision of the method was assessed by evaluating the interday and intraday 
relative standard deviations (RSDs). The intraday and interday RSD values were 0.32% (n 
= 5) and 0.33% (n = 6), respectively, for cyclosporine solutions of 0.247 mg/mL in 
methanol. The interday RSDs for samples of 0.2 mg/mL in 5% dextrose injection and 0.9% 
sodium chloride injection were 0.12% (n = 5) and 0.36% (n = 5), respectively (injection 
volumes of 20 µL); the values were 0.57% (n = 5) and 0.12% (n = 5) for 2.5 mg/ in 5% 
dextrose and 0.9% sodium chloride (injection volumes of 2 µL), respectively. For interday 
RSD evaluations, the samples were injected in duplicate on five consecutive days (i.e., n = 
5 denotes five times the average of two injections). 
The method was demonstrated to be stability-indicating by stress degradation of 
cyclosporine. Based on previously reported stress degradation results,7 acidic degradation 
was conducted to generate the relevant cyclosporine degradation products. Stress 
degradation testing was conducted on I.V. cyclosporine to rule out any peak overlap 
between the cyclosporine and the excipients, their degradation products, or the degradation 
products of cyclosporine. The test sample was prepared by adding I.V. cyclosporine 
solution (0.1 mL) to hydrochloric acid (5 mL, 1 N) which was then heated at 80 °C for four 
hours, cooled at room temperature, neutralized with sodium hydroxide (5 mL, 1 N), diluted 
with methanol to about 0.25 mg/mL, and filtered (0.2 mm); the sample was then assayed by 
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HPLC. The resulting chromatogram was compared with the chromatograms obtained from 
a solution of pure cyclosporine A (0.25 mg/mL in methanol) and reconstituted I.V. 
solutions of cyclosporine (0.20 mg/mL in 0.9% sodium chloride and 5% dextrose injection). 
No peak overlap was observed with the main cyclosporine peak (Figure 3.1). 
 
 
Figure 3.1 Representative chromatograms of (A) pure cyclosporine solution in methanol 
(0.25 mg/mL), (B) I.V. cyclosporine reconstituted in 0.9% sodium chloride (0.20 mg/mL), 
(C) I.V. cyclosporine reconstituted in 5% dextrose injection, and (D) I.V. cyclosporine 
solution submitted to forced degradation in acidic conditions (0.25 mg/mL). 
3.3.3 DLS testing 
  The particle size of test solutions was measured with a DLS system
m
 , The refractive 
index and viscosity of water were used in the calculation of the particle size (1.330 and 
0.8872 mPa·s). The reference sample was polystyrene (refractive index, 1.590). The 
measurements were performed in disposable cuvettes with a sample volume of 1.4 mL at 
25 °C. The attenuator was set to 9, the measurement position was set to 4.65 mm, and the 
measurement duration was 55 seconds. Due to the instrument‟s limit of detection, particle 
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sizing could only be performed on 2.5-mg/mL samples; the 0.2-mg/mL samples were too 
diluted to be evaluated using this instrument. 
3.3.4 Sample analysis 
Samples of 1.4 mL were aseptically withdrawn at time zero and after 3, 7, and 14 
days. The samples were assayed immediately without filtration or dilution. Concentrated 
samples (2.5 mg/mL) were evaluated visually, by DLS, and by HPLC (injection volume, 2 
mL). The diluted samples (0.2 mg/mL) were evaluated visually and by HPLC (injection 
volume, 20 mL). Visual inspections were performed with the unaided eye. The test 
solutions were visually examined in normal fluorescent light for color change and evidence 
of precipitation. The DLS measurements were performed in triplicate; the HPLC 
measurements were performed in duplicate, with acceptance specifications of <1% of the 
difference between both injections and calculated cyclosporine peak purity of >99.99% 
(based on the similarity index between 190 and 250 nm). The sterility of the cyclosporine 
solutions was not evaluated in this study. 
3.3.5 Data analysis 
The stability of cyclosporine was determined by evaluating the percentage of the initial 
concentration remaining at each time point. Stability was defined as a recovery of >90% of 
the initial concentration of cyclosporine, with a variation of <10% of the initial micelle 
average size (as indicated by DLS). 
3.4 Results and discussion 
As shown in Table 3.1, recovered cyclosporine stored in polypropylene-polyolefin 
bags was > 98% for all samples after 14 days at 25 °C (5% dextrose injection, 0.9% sodium 
chloride injection, 0.2 and 2.5 mg/mL). Furthermore, visual inspection did not find any 
evidence of physical change. The average particle size and the polydispersity index were 
unchanged during the study for the 2.5-mg/mL samples in both 0.9% sodium chloride and 5% 
dextrose injection (Table 3.2). The 0.2-mg/mL sample could not be evaluated because the 
concentration was below the limit of detection of the method; however, because a 
concentration of 2.5 mg/mL is considered a worst-case scenario in terms of physical 
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stability, no changes would be expected for the 0.2-mg/mL samples, as confirmed by visual 
inspection. Based on these results, no significant adsorption or chemical or physical change 
occurred when I.V. cyclosporine solution was stored in polypropylene–polyolefin 
containers for a period of 14 days at 25 °C.  
Table 3.1 Stability of I.V. Cyclosporine in Polypropylene-Polyolefin Bags
a
 
Norminal 
Cyclosporine 
Concentration and 
Diluent 
Mean ± S.D Initial 
Cyclosporine 
Concentration 
(mg/mL) 
Mean ± S.D Initial Concentration Remaining 
 
Day 3 Day 7 Day 14 
0.2 mg/mL 
5% dextrose 
0.207 ± 0.001 98.9 ± 0.6 99.1 ± 0.6 98.7 ± 0.8 
0.2 mg/mL 
0.9% sodium 
chloride 
0.206  ± 0.001 99.7 ± 0.3 99.8 ± 0.2 99.7 ± 0.3 
2.5 mg/mL 
5% dextrose 
2.49 ± 0.02 99.4 ± 0.7 99.0 ± 0.8 99.3 ± 0.7 
2.5 mg/mL 
0.9% sodium 
chloride 
2.50  ± 0.01 99.2 ± 0.3 99.2 ± 0.4 99.4 ± 0.5 
a
 Calclations are for triplicate samples, each sample was assayed in duplicate (n = 3×2) 
 
 
 
 
 
 
Table 3.2 Micelle Size Distribution of I.V. Cyclosporine 2.5 mg/mL Stored in 
Polypropylene–Polyolefin Bagsa 
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Diluent Mean ± S.D. Average Particle Size (nm) 
[mean ± S.D. Polydispersity Index] 
 Initial Day 3 Day 7 Day 14 
5% dextrose 13.77 ± 0.28 
[0.13 ± 0.05] 
13.85 ± 0.12 
[0.07 ± 0.04] 
14.24 ± 0.26 
[0.11 ± 0.06] 
14.23 ± 0.23 
[0.11 ± 0.07] 
0.9% sodium 
chloride 
12.90 ± 0.05 
[0.06 ± 0.01] 
12.92 ± 0.02 
[0.03 ± 0.01] 
13.19 ± 0.16 
[0.07 ± 0.02] 
13.07 ± 0.18 
[0.07 ± 0.01] 
a
 Calculations are triplicate samples; each sample was assayed in triplicate (n = 3×3) 
Cyclosporine recovery of >95% for each sample stored in polypropylene syringes 
after seven days at 25 °C (5% dextrose injection, 0.9% sodium chloride injection, 0.2 and 
2.5 mg/mL) was evaluated by HPLC. No physical change was detected by visual inspection. 
However, after only one day an impurity appeared on the HPLC chromatogram at a relative 
retention time of 1.45 (relative to the cyclosporine peak). After seven days, the 
polypropylene syringe stability study was terminated, as the impurity had increased 
significantly. This new impurity only appeared in the polypropylene syringe study and was 
never observed in the polypropylene–polyolefin container study. 
Further investigations were performed to determine the origin of the impurity. A 
placebo solution corresponding to cyclosporine 2.5 mg/mL in 5% dextrose injection was 
prepared using polyoxyethylated castor oil, alcohol, and 5% dextrose injection, and the 
black rubber component of the syringe plunger was immerged in the solution. The same 
impurity was detected after one day of exposure at 25 °C (Figure 5.1 and 5.2). It was 
concluded that an ingredient used in the manufacture of the black rubber component of the 
syringe plunger could be leached by the ingredients of the I.V. cyclosporine preparation. 
Even though the presence of additives did not appear to have a detrimental influence on the 
chemical stability of cyclosporine, the leached additive could pose a toxicity hazard. 
Therefore, this kind of polypropylene syringes with rubber component cannot be 
recommended for the storage of I.V. cyclosporine solutions. 
As polypropylene syringes are commonly used to transfer I.V. cyclosporine during 
the preparation of I.V. cyclosporine solutions, an additional test was performed to evaluate 
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whether any additive leached during short periods of contact with polypropylene. Solutions 
of undiluted I.V. cyclosporine (50 mg/mL) of 0.4 and 1 mL were stored for 10 minutes in 
1- and 5-mL polypropylene syringes. Each sample was prepared in triplicate, diluted with 5% 
dextrose injection to a total volume of 20 mL, and assayed by HPLC (injection volume, 100 
µL). The leaching additive could not be detected; therefore, polypropylene syringes 
appeared to be adequate for sampling and transferring I.V. cyclosporine solutions when the 
period of contact was less than 10 minutes. 
3.5 Conclusion 
Samples of I.V. cyclosporine solutions of 0.2 and 2.5 mg/mL diluted in 0.9% 
sodium chloride injection or 5% dextrose injection and stored at 25 °C in polypropylene–
polyolefin bags were physically and chemically stable for at least 14 days. When stored in 
polypropylene syringes, the I.V. cyclosporine solutions were contaminated by an impurity 
within 1 day; however, the short-term (i.e., ≤10 minutes) use of the syringes for the 
preparation and transfer of I.V. cyclosporine solution is considered safe. 
3.6 Materials and Instruments 
a 
Cyclosporine 50 mg/mL solution, Novartis, East Hanover, NJ, lot S0034 and lot S0040. 
b 
Baxter Corp., Mississauga, Ontario, Canada, lot W9F22C2. 
c 
Baxter Corp., Mississauga, Ontario, Canada, lot W9C26C3. 
d 
Luer-Lok, Becton-Dickinson, Mississauga, Ontario, Canada. 
e 
Aviva 250 mL capacity bags, Mississauga, Ontario, Canada. 
f 
DGU-20, Shimadzu Corporation, Kyoto, Japan. 
g 
SIL-20AC, Shimadzu Corporation.  
h 
LC-20AD, Shimadzu Corporation. 
I 
Zorbax, SB-C18, 4.6 × 250 mm, Agilent technologie, Mississauga, Ontario,Canada. 
j 
CTO-20AC, Shimadzu Corporation. 
70 
 
k 
SPD-M20A, Shimadzu Corporation. 
l 
Cyclosporine 98%, AK Scientific Inc., Union City, CA, lot H890. 
m 
Zetasizer NS, Malvern Instruments Ltd.,Malvern, Worcestershire, U.K. 
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4.1 Abstract 
The stability of cyclosporine solutions in 0.9% sodium chloride injection (NS) or 5% 
dextrose injection (D5W) stored in ethylene-vinyl acetate (EVA) containers was evaluated 
and the adsorption of cyclosporine to EVA surface was studied. The cyclosporine solutions 
(0.2 and 2.5 mg/mL) were aseptically prepared by injecting Sandimmune® IV in prefilled 
EVA containers and stored at 25°C. Chemical stability was measured using a stability-
indicating high-performance liquid chromatography (HPLC) method. Physical stability was 
assessed by visual inspection and a dynamic light scattering (DLS) method. Based on the 
chemical and physical stability data, EVA containers can be used to store cyclosporine 
injections of 0.2 mg/mL in D5W and NS injections for 7 days. Concentrated 2.5 mg/mL 
cyclosporine solutions in D5W and NS injections can be stored in EVA bags at least 14 
days. However, adsorption of cyclosporine on EVA containers was observed. The 
adsorption was studied on the test solutions which were first prepared in a glass beaker and 
then transferred into EVA containers. The adsorption kinetics was evaluated using three 
classic models (external diffusion model, Weber-Morris model, modified Weber-Morris 
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model) and two novel numerically resolved adsorption models based on Fick‟s first law. 
The results showed that the internal diffusion may be the rate-limiting step. The modified 
Weber-Morris model could successfully describe the adsorption process (0.2 mg/mL  
cyclosporine  in NS and D5W) with good correlation coefficients (> 0.97) and low 
variation (predicted vs observed) of < 9%. However, the rapid adsorption events on surface 
sites were not taken into account. In this study, two novel diffusion models were 
established regarding rapid adsorption, contact surface area and volume of solution. The 
models were numerically resolved and very good fitting results were achieved with 
variation < 8%. The model based on internal diffusion could be applied to predict long-term 
drug stability  with variation < 2%. 
4.2 Introduction 
Cyclosporine is a neutral and hydrophobic cyclic undecapeptide. It is a potent 
immunosuppressive agent used to reduce the risk of rejection following allogenic organ 
transplantations. Intravenous cyclosporine for injection contains cyclosporine (50 mg/mL), 
polyoxyethylated castor oil (650 mg/mL) and ethanol (qs). According to the product 
monograph, this latter preparation requires dilution to concentrations between 0.5 mg/mL 
to 2.5 mg/mL with 0.9% sodium chloride injection (NS) or 5% dextrose injection (D5W) 
prior to administration. Dilutions as low as 0.2 mg/mL are routinely used in pediatric 
hospitals. Diluted preparations should be slowly administered by intravenous infusion over 
2 to 6 hours {Novartis, 2011 #380}. 
Due to its physicochemical properties, cyclosporine is prone to adsorption on the 
surface of plastic containers or tubings, resulting in inadequate dosing {McLeod, 1992 
#382}. Polyvinyl chloride (PVC) containers and tubings are not acceptable for intravenous 
cyclosporine as cyclosporine is significantly adsorbed on PVC surfaces. The extent of drug 
loss depends on concentration, diluent and container composition. For instance, 
cyclosporine adsorption on the surface of PVC containers is more important when it is 
diluted in NS and is less important when it is diluted in D5W {Shea, 1989 #388;Ptachcinski, 
1986 #383}. In addition, the leaching of plasticizer di-2-ethyl hexyl phtalate (DEHP) from 
PVC containers to parenteral solutions could constitute a health hazard {Allwood, 1996 
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#7;FDA, 2011 #392}. The polyoxyethylated castor oil contained in intravenous 
cyclosporine injections can extract phthalates from PVC containers and may constitute 
another limitation for the use of PVC container with cyclosporine injections (Novartis 
2011). Glass containers are not a convenient alternative. They are breakable, are not 
flexible like plastic containers and venting is required to avoid pressure change during 
filling or emptying. Thus, non-PVC plastic containers are the only practical remaining 
option for the preparation of intravenous cyclosporine. Very little information is available 
regarding the stability of cyclosporine in such containers. Our group previously reported 
the stability and compatibility of intravenous cyclosporine injections in polypropylene-
polyolefin containers (PP-PO, Aviva®) and PP syringes (Luer-Lok®)  {Li, 2011 #394}. 
Cyclosporine injections (0.2 mg/mL and 2.5 mg/mL) in D5W and NS were physically and 
chemically stable for a period of at least 14 days in PP-PO containers. However, storage in 
PP syringes with rubber plunger could not be recommended. Some additives were found to 
leach from the rubber within 24 h because of the presence of polyoxyethylated castor oil. 
The absence of plasticizers in ethylene-vinyl acetate (EVA) containers is beneficial 
for the storage of parenteral preparations {Driscoll, 2006 #173;Trissel, 2003 #219}. Even if 
EVA containers are readily available, only limited stability and compatibility data are 
currently reported for these containers. One of these studies reports a significant insulin loss 
during infusion because of drug adsorption {Doglietto, 1989 #395} {Doglietto, 1989 #395}. 
Insulin and cyclosporine present some structural similarities as the former is a small peptide 
and the latter is a small cyclic peptide. Therefore, adsorption of cyclosporine to EVA 
surfaces is a concern and its significance will depend on cyclosporine properties, EVA 
properties, diluent, contact surface area, concentration and storage interval. 
The objective of this study is to investigate the compatibility of cyclosporine 
injections in D5W and NS with EVA containers. 
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4.3 Methods 
4.3.1 Real conditions stability study 
  The samples used for the real conditions stability study were aseptically prepared at 
Ste-Justine Pediatric Hospital (Montreal, Canada) using their standard procedures. The 
cyclosporine test solutions (0.2 and 2.5 mg/mL) in 100 mL D5W
a
 and NS
b
 were prepared in 
triplicate by injecting Sandimmune® IV
c
 in prefilled EVA containers
d
. The containers were 
then transferred to Université de Montréal to be stored at 25°C (23-27°C) in an incubator. 
Aliquots (1 mL) were aseptically withdrawn 12 h after the preparation (initial time point) 
and after 3, 7 and 14 days. These samples were evaluated by HPLC, DLS and visual 
inspection. 
4.3.2 Adsorption study  
Cyclosporine test solutions (0.2 and 2.5 mg/mL, 350 mL) were prepared in glass 
beakers by diluting Sandimmune® IV
c
 with D5W
a
 and NS
b
. Each preparation was then 
transferred in 3 empty EVA containers
d
 using a 50 mL-glass syringe (100 mL per 
container). The containers were stored at 25°C (23-27°C) in an incubator. Aliquots (1 mL) 
were aseptically withdrawn from the beaker prior to the transfer in the EVA container and 
also after 5 min, 4 h, 8 h, 12 h, 24 h and 72 h following the transfer. These samples were 
evaluated by HPLC and visual inspection. 
4.3.3 HPLC assay 
  Content assay was performed using a stability-indicating HPLC method which was 
previously reported by our group (Li, Forest et al. 2011). Triplicated injection volumes of 
20 μL and 2 μL were utilized for cyclosporine solution samples of 0.2 and 2.5 mg/mL, 
respectively. 
4.3.4 Dynamic Light Scattering 
Due to the surfactant nature of polyoxyethylated castor oil, the cyclosporine 
solutions are micellar. The micelle size distribution of test solutions was measured in water 
by dynamic light scattering (Zetasizer NS, Malvern Instruments Ltd.). Triplicated 
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measurements were performed in low-volume disposable cuvettes (0.5 mL) at 25°C. An 
attenuator value of 8 or 9, a measurement position of 4.65 mm and duration of 60 s were set 
for each measurement. Due to the sensitivity of the instrument, particle sizing could only be 
performed on 2.5 mg/mL samples. The samples of 0.2 mg/mL were too diluted to be 
evaluated by this instrument. 
4.3.5 Data analysis of HPLC 
 The stability of cyclosporine was determined by evaluating the percentage of the 
initial concentration remaining at each time point. Stability was defined as a recovery of  > 
90% of the initial concentration of cyclosporine, with a variation of <10% of the initial 
micelle average size (as indicated by DLS). 
4.3.6 Visual inspection  
Visual inspections were performed with the unaided eye to check if color change 
and precipitation occurred. 
4.3.7 Data analysis of DLS 
Stability was defined as the absence of any visual evidences of instability, a 
recovery of more than 90% of the initial concentration measured by HPLC and a variation 
of less than 10% in the initial size measured by DLS. Furthermore, DLS polydispersity 
index larger than 0.5 was considered unacceptably large {Patravale, 2004 #1161}. 
Averaged results are reported with their standard deviation (mean ± sd). HPLC and DLS 
measurements were repeated 3 times for each analyzed sample. Statistical significance of 
differences was evaluated using the Student‟s T-test and a p < 0.05 was considered 
significant. 
For the adsorption study, the adsorbed mass of cyclosporine (mi) on EVA containers 
was calculated for each time interval (i) using the measured concentration (ci), the residual 
volume after sampling (vi), the measured initial concentration (c0), the initial volume 
(v0=100 mL) and the sampled volume (vs=1 mL). Based on the principle of mass 
conservation (Equation 1), the sum of the adsorbed mass (mi), the mass in solution within 
the container (ci×vi) and the cumulative mass in the sampled solutions (summation term) 
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will always remain equal to the initial mass (c0×v0). As illustrated by Equations 2 and 3, the 
adsorbed mass (mi) can easily be calculated, and normalized (qi) per unit of container 
surface area (s=410 cm
2
). 
(1) 𝑐0 × 𝑣0 = 𝑚𝑖 + 𝑐𝑖 × 𝑣𝑖 +  𝑐𝑗 × 𝑣𝑠
𝑖
𝑗=1  
(2) 𝑚𝑖 = 𝑐0 × 𝑣0 − 𝑐𝑖 × 𝑣𝑖 −  𝑐𝑗 × 𝑣𝑠
𝑖
𝑗=1  
(3) 𝑞𝑖 = 𝑚𝑖 𝑠  
4.4 Results and discussion 
4.4.1 Real conditions stability study  
Usually, the injection preparations should be monitored in the range of 90-110% of 
intended concentrations. As reported in Table 4.1, for the 2.5 mg/mL solutions, the 
concentrations at the initial time point were 2.47 mg/mL and 2.45 mg/mL in D5W and NS. 
These concentrations remained stable for at least 2 weeks. Furthermore, the micelle size 
distribution was not affected for the duration of the study (Table 4.2). No visual evidences 
of instability were observed at any time point. Therefore, cyclosporine injection was stable 
at least 2 weeks when diluted in D5W or NS and stored at 25°C in EVA containers. 
The 0.2 mg/mL solutions demonstrated evidences of incompatibility (Table 4.1). 
Initial concentrations were unusually low due to very small amount of sampling. 
Nevertheless, the concentrations fell in the acceptable range of 90-110% of the targeted 
concentration (0.2 mg/mL) : 0.185 mg/mL in D5W and 0.186 mg/mL in NS, 
respectively.The concentrations decreased with time and fell below 90% of initial after 2 
weeks. Even if concentration decreased more than 10%, no new impurities were detected 
by HPLC, suggesting adsorption as the root cause of this incompatibility. No visual 
evidence of degradation was observed at any time point. Based on these results, EVA 
containers could be considered acceptable to store 0.2 mg/mL cyclosporine injections in NS 
and D5W for a period of 1 week at 25°C to maintain a concentration of cyclosporine above 
90% of the initial concentration. However, clinically significant adsorption of cyclosporine 
with the EVA container was observed at this concentration after 2 weeks. As this 
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phenomenon was not observed with polypropylene-polyolefin (PP-PO) containers (Li, 
Forest et al. 2011), these latter containers are highly preferable to store cyclosporine 
injections. 
Cyclosporine adsorption on EVA containers was slightly reduced in NS compared to 
D5W. Interestingly, this result differed from previously reported adsorption results with 
PVC containers, in which the adsorption of cyclosporine in NS solutions was more 
significant than in D5W solutions (Ptachcinski, Logue et al. 1986; Shea, Ptachcinski et al. 
1989). It can be assumed that the adsorption mechanism is closely related to vehicles.  
D5W and NS differ in ionic strength. It has been reported that a greater ionic strength in 
solution may decrease adsorption when electrostatic interactions are involved between the 
solute and the polymer {Palmgren, 2006 #481}. Considering the chemical structure of EVA 
and cyclosporine, the intermolecular interaction maybe predominated by electrostatic 
dipole-dipole attraction or hydrogen interaction, which  arise from polar groups such as  -
C=O in EVA and -COOH, -NH2 in  cyclosporine. The competing ions in NS may reduce 
cyclosporine adsorption on EVA.  
4.4.2 Adsorption study 
The stability study was repeated under slightly different conditions to model the 
kinetics of adsorption for the 0.2 mg/mL solutions and to confirm the absence of clinically 
relevant adsorption for the 2.5 mg/mL solutions. This adsorption study was therefore 
designed to better control the variables of the experiments. The solutions were first 
prepared in a glass beaker and then each solution was transferred to 3 EVA containers. This 
allowed the accurate preparation of a larger volume of solution and also allowed 
determination of a real initial concentration prior to any adsorption event. 
Results of the adsorption study are listed in Table 4.3. Cyclosporine solutions in 
D5W and NS decreased to 98.6% and 99.4%, respectively after only 5 min of contact time 
with EVA container. This suggested rapid adsorption occurred during the very first minutes 
of contact. This difference was statistically significant in both cases. After 3 days of storage, 
similar cyclosporine recovery was observed for both the real conditions study and the 
adsorption study (Tables 4.1 and 4.3). 
79 
 
Again, no significant adsorption was observed for the 2.5 mg/mL solutions after 3 
days, confirming the results of the real conditions stability study. Assuming the adsorption 
saturated after 2 weeks, the saturated adsorption in 0.2 mg/mL D5W injection is estimated 
as 2.27 mg in 100 mL EVA bag. Generally, the adsorption amount should increase with the 
equilibrium concentration, thus, the saturated adsorption in 2.5 mg/mL should be much 
higher than 2.27 mg. Based on it, the concentration should be less than 99% of initial for 
2.5 mg/mL injections. Such difference should be captured by HPLC. However, no 
significant decrease in concentration was observed in this study, indicating that negligible 
amount of adsorption occurred in high concentration of injections. It has been reported that 
surfactant polysorbate 20 is effective to reduce protein and peptide adsorption to glass and 
polypropylene surface because of greater surfactant-surface interactions than drug-surface 
interactions {Duncan, 1995 #404}. Similarly, the greater concentration of polyoxyethylated 
castor oil in the 2.5 mg/mL injections compared to 0.2 mg/mL injectins, maybe associated 
with a reduced adsorption of cyclosporine on EVA surfaces. 
As pictured in Figure 4.1, the adsorption process involves three steps resulting in 
the actual adsorption or uptake: (1) diffusion from the bulk to the surface of the interfacial 
liquid film (bulk diffusion); (2) diffusion through the interfacial liquid film (external 
diffusion); and (3) diffusion within the polymeric membrane (internal diffusion). This 
model of adsorption is an adaptation for polymeric membranes of the intraparticle diffusion 
model {Igwe, 2007 #405}. The intraparticle diffusion model was developed to describe the 
adsorption of small molecules to inorganic or resin beads {Wu, 2009 #439;Plazinski, 2009 
#440}. The rate of adsorption is controlled by its slowest step. For physical adsorption, 
adsorption is very rapid and the rate is controlled by one of the diffusion steps {Alzaydien, 
2009 #469;Sekine, 2002 #420}. Considering timescale, viscosity and Brownian motion, 
diffusion in the bulk did not limit the rate of adsorption for the current study. Therefore, the 
rate of adsorption was controlled by external or internal diffusion. 
The adsorption kinetics of cyclosporine 0.2 mg/mL in D5W and NS in EVA 
containers was evaluated using three classical adsorption models and two numerically 
resolved adsorption models based on Fick‟s first law. The five models are summarized in 
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Table 4.4 along with calculated parameters. The goodness of the fit for each model was 
evaluated using the coefficient of variation of the root mean squared errors (CVRMSE). 
4.4.2.1 External diffusion model 
When external diffusion controls the rate of adsorption, the adsorbed amount is equal 
to the transfer of solute across the liquid film according to Fick‟s first law. The rate of 
external diffusion is illustrated by Equation 4 where de (cm
2
·h
-1
) is the diffusion coefficient 
in the interfacial liquid film, le (cm) is the thickness of the interfacial liquid film, v (cm
3
) is 
the volume of solution, s (cm
2
) is the surface of the polymeric membrane and t (h) is the 
time. cs and c (mg·cm
-3
) correspond to the concentration at the surface of the membrane 
and in the bulk of the solution respectively, both vary with time. An external diffusion 
parameter (ke, h
-1
) is defined from de, le and v to simplify the problem. Assuming very fast 
uptake, cs can be assumed to be zero and Equation 4 can be integrated as Equation 5. 
(4) −
𝜕𝑐
𝜕𝑡
=
𝑑𝑒  𝑠  𝑐−𝑐𝑠 
𝑣 𝑙𝑒
= 𝑘𝑒  𝑐, for 𝑘𝑒 =
𝑑𝑒  𝑠
𝑣 𝑙𝑒
 and 𝑐𝑠 = 0 
(5) −𝑙𝑛 
𝑐
𝑐0
= 𝑘𝑒  𝑡 
The validity of this model can be verified by linear regression of a plot of -ln (c/c0) as a 
function of t. The slope of this regression corresponds to the external diffusion constant ke. 
This calculation was performed and resulted in an R
2
 of 0.3448 for the 0.2 mg/mL solution 
in D5W and an R
2
 of 0.5473 for the 0.2 mg/mL solution in NS. These poor correlation 
coefficients as well as the poor CVRMSE (Table 4.4) suggested external diffusion was not 
the rate limiting step. 
4.4.2.2 Weber-Morris model for internal diffusion 
The Weber-Morris model is a mathematical approximation describing adsorption 
when internal diffusion is the rate-limiting step. In this model, the amount of adsorption is 
proportional to t
1/2
 {Ozer, 2006 #472;Qiu, 2009 #484}. The Weber-Morris model is 
illustrated by Equation 6 where q (mg·cm
-2
) is the amount of adsorption at time t (h) and ki 
(mg·cm
-2
·h
-0.5
) is the internal diffusion constant. 
(6) 𝑞 = 𝑘𝑖𝑡
1 2   
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When the plot of the amount of adsorption (q) versus the square root of time (t) is linear 
and passes through the origin, internal diffusion is the only rate-limiting step. The linear 
fitting results are shown in Table 4.4.  R
2  
is 0.9669 and 0.9012 for 0.2 mg/mL cyclosporine 
in NS and in D5W. However, this was not the case for cyclosporine 0.2 mg/mL in EVA 
containers as significant adsorption was rapidly observed resulting in CVRMSE > 10% 
(Table 4. 4). 
4.4.2.3 Modified Weber-Morris model 
Ozer et al. (Ozer, Akkaya et al. 2006) investigated the biosorption of dyes on green 
algae and also found the linear regression did not pass through the origin. They proposed 
the modified Equation 7. This equation was more accurate when adsorption rate was 
influenced both by internal and external diffusion processes. The parameter m (mg·cm
-2
) 
was introduced by Igwe (Igwe and Abia 2007) and reflects the rapid contribution of 
external diffusion, however, the parameter m is not clearly defined in terms of  adsorption 
mechanism. Rapidly occurring events could include readily accessible adsorption sites at 
the surface of the polymeric membrane. Larger values of m are representative of significant 
occurrence of adsorption at the surface sites. (Wu, Tseng et al. 2009).  
(7) 𝑞 = 𝑘𝑖𝑡
1 2 + 𝑚 
With regards to the current study, a linear regression was performed on the plots of the 
adsorbed amount of cyclosporine for the 0.2 mg/mL solution in D5W and the 0.2 mg/mL 
solution in NS against the square root of time (Figure 4.2). Good correlation coefficients 
and CVRMSE (Table 4.4) were achieved in both cases showing internal diffusion was the 
rate limiting step with occurrence of adsorption on readily available sites. 
4.4.2.4 Numerical resolution of the combined external and internal diffusion model 
We propose a comprehensive model of adsorption taking into account a rapid 
contribution of surface sites (q0), an external diffusion constant (ke) as well as an internal 
diffusion constant (ki). This model was constructed from the differential equations 
describing the external and the internal diffusion as derived from Fick‟s first law of 
diffusion. The rate of external diffusion is illustrated by Equation 8 where de (cm
2
·h
-1
) is 
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related to the diffusion coefficient in the interfacial liquid film and le (cm) is the thickness 
of the interfacial liquid film cs and c (mg·cm
-3
) correspond to the concentration at the 
surface of the membrane and in the bulk of the solution respectively, both vary with time. 
The external diffusion parameter (ke, cm·h
-1
) is defined from de and le to simplify the 
problem. 
(8) 
𝜕𝑞
𝜕𝑡
=
−𝑑𝑒   𝑐𝑠−𝑐 
𝑙𝑒
= −𝑘𝑒 𝑐𝑠 − 𝑐 , for 𝑘𝑒 =
𝑑𝑒
𝑙𝑒
 
The rate of internal diffusion was similarly defined (Equation 9). For internal diffusion, a 
front of diffusion was assumed to progress within the polymeric membrane. The length of 
this front of diffusion (li, cm) varied with time. Concentrations where assumed equal to 
zero at position li and equal to cs at the surface of the polymeric membrane. The adsorptive 
capacity (ai, mg·cm
-3
) of the polymeric membrane was defined from the quantity of drug it 
can adsorb (q, mg·cm
-2
) per unit of length (li, cm), and is related to the chemistry and 
structure of the polymeric membrane. di (cm
2
·h
-1
) is the diffusion coefficient within the 
containers. Thus, ki (mg·cm·h
-1
) was defined from ai and di and was assumed constant 
during the adsorption process. 
(9) 
𝜕𝑞
𝜕𝑡
=
−𝑑𝑖   0−𝑐𝑠 
𝑙𝑖
=
𝑘𝑖  𝑐𝑠
𝑞
, for 𝑎𝑖 =
𝑞
𝑙𝑖
 and 𝑘𝑖 = 𝑎𝑖 𝑑𝑖  
Both differential equations (Equations 8 and 9) can be combined to obtain Equation 10. 
(10) 
𝜕𝑞
𝜕𝑡
= 𝑘𝑒  𝑐 −
𝜕𝑞
𝜕𝑡
 𝑞
𝑘𝑖
 = 𝑘𝑒  𝑐0 −
𝑞  𝑠
𝑣
−
𝜕𝑞
𝜕𝑡
 𝑞
𝑘𝑖
 , for 𝑐 = 𝑐0 −
𝑞  𝑠
𝑣
 
In order to take into account the adsorption sites which are readily available at the surface 
of the polymeric membrane, q0 (mg·cm
-2
) was not assumed null. Therefore c0 (mg·cm
-3
) 
was defined from the concentration of the preparation (cprep) and q0 as illustrated by 
Equation 11. 
(11) 𝑐0 = 𝑐𝑝𝑟𝑒𝑝 −
𝑞0  𝑠
𝑣
 
Equations 10 and 11 can be combined as Equation 12. This equation was numerically 
resolved as an attempt to evaluate the contribution of each mechanism to the total 
adsorption observed for cyclosporine in EVA containers.
e
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(12) 
𝜕𝑞
𝜕𝑡
= 𝑘𝑒  𝑐𝑝𝑟𝑒𝑝 −
𝑞0  𝑠
𝑣
−
𝑞  𝑠
𝑣
−
𝜕𝑞
𝜕𝑡
 𝑞
𝑘𝑖
  
As reported in Table 4.4, very good CVRMSEs were obtained using this mathematical 
model. CVRMSE was not affected by ke as long as extremely large values were used 
suggesting again that external diffusion was not a limiting factor of adsorption  rate. 
4.4.2.5 Numerical resolution of the internal diffusion model 
Considering the negligible contribution of external diffusion, an internal diffusion-
only model was defined from Equation 9 resulting in Equation 13. Equation 13 was 
numerically resolved to determine the parameters ki and q0 for this model of diffusion.
e
 
(13) 
𝜕𝑞
𝜕𝑡
=
𝑘𝑖  𝑐𝑠
𝑞
=
𝑘𝑖
𝑞
 𝑐𝑝𝑟𝑒𝑝 −
𝑞0  𝑠
𝑣
−
𝑞  𝑠
𝑣
  for 𝑐𝑠 = 𝑐 = 𝑐0 −
𝑞  𝑠
𝑣
 and 𝑐0 = 𝑐𝑝𝑟𝑒𝑝 −
𝑞0  𝑠
𝑣
 
This model of diffusion very accurately described the adsorption of cyclosporine on the 
surface of EVA containers (Table 4.4). Like the modified Weber-Morris model, the internal 
diffusion model uses only two parameters (ki and q0). This latter model is usually applied to 
the adsorption of solute from a liquid to solid particles and was not reported yet for the 
adsorption of pharmaceutical compounds to membranes. The proposed internal diffusion 
model also takes into account the rapid adsorption events resulting from readily accessible 
adsorption sites. Also, the proposed model takes into account the volume of solution, the 
surface of the polymeric membrane and the initial concentration of the preparation to 
evaluate the stability of the drug. These three important variables are overlooked by the 
modified Weber-Morris model. Furthermore the proposed internal diffusion model was 
numerically resolved and not only an approximation of  Fick‟s first law of diffusion. 
4.4.2.6 Validation of the adsorption model 
Equation 13 and its previously optimized parameters were utilized to build a 
predictive model of adsorption of cyclosporine in NS and D5W. Results from the real 
conditions stability study were compared to data generated using this model. As shown in 
Table 4.5, differences between the predicted and the observed data were very small. 
Demonstration of the accuracy of this model was performed by calculating the coefficient 
of variance of the root of mean squared error. 
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4.5 Conclusion 
Based on chemical and physical stability data, EVA containers can be used to store 
cyclosporine injections of 0.2 mg/mL in D5W and NS injections for 7 days. Concentrated 
2.5 mg/mL cyclosporine solutions in D5W and NS injections can be stored in EVA bags at 
least 14 days. However, adsorption of cyclosporine on EVA containers was observed. The 
study of the adsorption kinetics showed that the internal diffusion may be the rate-limiting 
step. 
The modified Weber-Morris model could successfully describe the adsorption 
process.  In this study, a novel internal diffusion model was established regarding rapid 
adsorption, contact surface area and volume of solution. This model was numerically 
resolved and very good fitting results were achieved.  
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4.7 Footnotes 
a
Sandimmune IV, 50 mg/mL, Novartis Canada, lot S0040, exp MAR 2013. 
b
Dextrose 5% injection, Baxter Canada, Lot W1C09B0, EXP JUN 2012. 
c
Normal saline injection, Baxter Canada, Lot W1C25A0, EXP SEP 2012. 
d
EVA containers, 250 mL, Baxa, Lot 757280, EXP DEC 2012. 
e
Equation simplification, numerical resolution and parameter optimization using 
Mathematica 8.0 (Wolfram Research, Inc.) are illustrated in the supplementary materials. 
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Figure 4.1 Adsorption process 
 
 
 
Figure 4.2  Modified Weber‐Morris adsorption model
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Table 4.1 Real conditions stability study
a 
 
Solution 
Initial concentration
b
 
(mg/mL) 
Fraction of initial concentration recovered
 
3 days (25°C) 7 days (25°C) 14 days (25°C) 
0.2 mg/mL in D5W 0.1854 ± 0.0060 95.9% ± 0.2% 92.0% ± 0.4% 87.5% ± 0.2% 
0.2 mg/mL in NS 0.1860 ± 0.0101 95.8% ± 0.4% 92.6% ± 0.7% 89.1% ± 0.8% 
2.5 mg/mL in D5W 2.472 ± 0.047 100.1% ± 0.5% 100.6% ± 0.6% 100.3% ± 0.3% 
2.5 mg/mL in NS 2.451 ± 0.046 100.1% ± 0.3% 100.6% ± 0.3% 101.4% ± 0.4% 
 
a
 Each value is the average result of three containers. 
b
Initial sampling was performed after 12h. 
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Table 4.2 Micelles size distribution by dynamic light scattering 
 
 
Solution 
Initial
a
 
 
Micelle size distribution 
3 days (25°C) 7 days (25°C) 14 days (25°C) 
2.5 mg/mL in D5W
b
     
Z‐Avg (nm) 13.71 ± 0.09 14.24 ± 0.26 14.06 ± 0.07 14.09 ± 0.09 
PDI 0.042 ± 0.010 0.056 ± 0.027 0.035 ± 0.005 0.032 ± 0.008 
2.5 mg/mL in NS
b
     
Z‐Avg (nm) 12.86 ± 0.05 12.83 ± 0.05 12.71 ± 0.09 12.71 ± 0.03 
PDI 0.022 ± 0.006 0.029 ± 0.005 0.026 ± 0.005 0.017 ± 0.001 
a
Initial sampling was performed after 12h. 
b
Average of triplicated preparations and triplicated analyses (n=3x3) 
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 Table 4.3 Adsorption study 
 
 
Solution 
Initial concentration
a
 
(mg/mL) 
Fraction of initial concentration recovered 
5 min (25°C) 4 h (25°C) 8 h (25°C) 12 h (25°C) 1 day (25°C) 3 days (25°C) 
0.2 mg/mL in D5W 0.1992 ± 0.0004 98.8% ± 0.5% 98.4% ± 0.3% 97.9% ± 0.1% 97.0% ± 0.1% 96.5% ± 0.2% 94.0% ± 0.1% 
0.2 mg/mL in NS 0.2056 ± 0.0003 99.4% ± 0.1% 98.8% ± 0.0% 98.6% ± 0.3% 97.8% ± 0.2% 96.9% ± 0.1% 95.3% ± 0.1% 
2.5 mg/mL in D5W 2.5128 ± 0.0076 100.1% ± 0.4% 100.0% ± 0.2% 100.0% ± 0.1% 100.4% ± 0.1% 100.4% ± 0.1% 100.5% ± 0.1% 
2.5 mg/mL in NS 2.4994 ± 0.0054 100.3% ± 0.1% 100.0% ± 0.2% 100.2% ± 0.2% 100.2% ± 0.1% 100.3% ± 0.2% 100.4% ± 0.3% 
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Table 4.4   Adsorption models 
  
Equation 
 
Cyclosporine 0.2 mg/mL in NS 
 
Cyclosporine 0.2 mg/mL in D5W 
 
External diffusion model  k e = 7.81e‐4 h-1 
R2 =0.5473 
k e = 9.82e‐4 h-1 
R2 =0.3448 
 
 
CVRMSE = 43.7% CVRMSE = 45.6% 
Weber‐Morris model  k i =2.82e‐4 mg cm-2 h-0.5 
R2 =0.9669 
k i =3.46e‐4 mg cm-2 h-0.5 
R2 =0.9012 
 
 
CVRMSE = 11.3% CVRMSE = 16.7% 
 
Modified Weber‐Morris model  k i = 2.58e‐4 mg cm-2 h-0.5  
R2 =0.9799 
k i = 2.82e‐4 mg cm-2 h-0.5 
R2 =0.9751 
 
 
m = 1.33e‐4 mg cm-2 m = 3.48e‐4 mg cm-2 
101 
 
101 
 
  CVRMSE = 8.82% CVRMSE = 8.40% 
 
External and internal diffusion model  k e > 1.93e‐2 cm h-1 
 
k e > 2.80e‐2 cm h-1 
 
 
k i =1.93e‐7 mg cm-1h-1 
 
k i =2.80e‐7 mg cm-1 h-1 
  q 0 = 2.59e‐4 mg cm-2 
 
q 0 = 5.53e‐4 mg cm-2 
  CVRMSE = 7.99% CVRMSE = 5.81% 
Internal diffusion model  k i = 1.93e‐7 mg cm-1 h-1 k i = 2.80e‐7 mg cm-1 h-1 
 
 
q 0 = 2.59e‐4 mg cm-2 q 0 = 5.53e‐4 mg cm-2 
  CVRMSE = 7.99% CVRMSE = 5.81% 
CVRMSE: Coefficient of variation of the root of mean squared error (predicted q vs. observed q)  
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Table 4.5 Validation of the adsorption model 
Solution  Concentration (mg/mL) 
 Initial 12 h 3 days 7 days 14 days 
0.2 mg/mL in D5W       
Measured  N/A 0.185 ± 0.006 0.178 ± 0.005 0.170 ± 0.005 0.162 ± 0.005 
Predicted  0.188 0.183 0.177 0.171 0.165 
Error   0.002 0.001 ‐0.001 ‐0.003 
CVRMSE 1.11%      
0.2 mg/mL in D5W       
Measured  N/A 0.186 ± 0.010 0.178 ± 0.010 0.172 ± 0.011 0.166 ± 0.010 
Predicted  0.187 0.183 0.178 0.173 0.16 
Error   0.003 0.000 ‐0.001 ‐0.002 
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CVRMSE 1.09%      
CVRMSE: Coefficient of variation of the root of mean squared error (predicted c vs. observed c)  
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Chapter Five  
5 Discussion 
The intravenous cyclosporine Sandimmune
®
 I.V. (Novartis) contains cyclosporine 
(50 mg/mL), polyoxyethylated castor oil (Cremophor EL) 650 mg/mL and ethanol 32.9% 
(by volume) {Novartis, 2011b #485}. Due to its hydrophobic nature, the adsorption of 
cyclosporine on plastic containers or administration sets is a potential issue {McLeod, 1992 
#382}.  Additionally, some additives in the container or sets may be leached due to higher 
concentration of Cremophor EL in the formulaion {Ptachcinski, 1986 #488}. Currently, 
non-PVC containers are widely used for the preparation of intravenous cyclosporine. It is 
imperative to evaluate their compatibility with cyclosporine injections. 
In the present project, a new stability-indicating HPLC method was developed and 
validated for the current stability study. There is numerous non-PVC containers used for 
preparation of intravenous cyclosporine administration. PP-PO bags, EVA bags and PP 
syringes are plasticizer- free and widely used clinically. This study has assessed the 
compatibility of these containers with intravenous cyclosporine injections, and attempted to 
provide adequate information required for clinical practice.   
5.1 Development of an HPLC method 
 
Several cyclosporine analytical methods have been reported. In brief, these methods 
include reverse phase HPLC (RP- HPLC) methods employing acetronitrile- or 
tetrahydrofuran-based mobile phases {Kumar, 2001 #1017}. In this study, a methanol-
based HPLC method was developed. Compared to the current USP method, this method 
used a mixture of methanol and water as mobile phase, which is more cost-effective and 
environmental favourable {Ankur M. Desai , 2011 #1195;Ankur M. Desai , 2011 #1195}.  
The main challenge of RP-HPLC method for cyclosporine analysis is the broadening 
peak due to inter-conversion of multiple conformations of cyclosporine, which sometimes 
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impacts separation efficiency {Nishikawa T., 1994 #486}.  The USP HPLC method 
recommends theoretical plates > 700 and a tailing factor < 1.5. In our study, the methanol-
based method was optimized by changing the ratio of methanol/water, and column 
temperature. The appropriate conditions were determined as: methanol/water was 86:14; 
column temperature was 50 
o
C, in which the theoretical plate number and tailing factor are 
1309, 1.052, respectively, indicating that a good separation could be achieved. The 
precision and accuracy assessments verified that the method had good repeatability and 
reproducibility. The intraday and interday RSD of repeated injections were 0.32% and 
0.33%, meeting the criterion < 1% regulated in USP and ICH guidelines. Accuracy was 
validated by standard additions. In the USP and ICH regulations, the acceptable criterion of 
recovered standard for final drug product is 98-102%. In this method, the recovered 
standard cyclosporine was between 99.80% and 100.1% (Velagaleti 2007).  
 In the method development, the stress degradation tests on both cyclosporine and 
intravenous cyclosporine were performed under acid condition. As shown in Figure 2.1, no 
interference occurred with cyclosporine after acid degradation. In the chromatogram of 
degraded intravenous cyclosporine, some new peaks (at 5.3 min and 12.7 min) appeared 
due to the degradation of Cremophor EL in the formulation. However, these peaks did not 
interfere with the cyclosporine peak. Peak purity was checked by PDA detector. The purity 
index of all cyclosporine peaks (190 nm to 600 nm) in the current study was higher than 
0.999, confirming no significant impurity coeluted with cyclosporine.  
According to USP and ICH guidelines, the method was validated to demonstrate 
stability-indicating, including suitability test, validation of specificity, linearity and range, 
detection limit, precision, accuracy and robustness. Based on these results, this method is 
suitable for stability tests of intravenous cyclosporine or routine assays. This method has 
been successfully used to identify impurity leached from syringe rubber, and studied 
cyclosporine stability in PP-PO bags and the adsorption in EVA containers.  
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5.2 Stability of intravenous cyclosporine stored in polypropylene 
syringes with rubber plunger  
In our preliminary stability tests, intravenous cyclosporine preparations of 0.2 and 2.5 
mg/mL in D5W and NS injections were prepared and transferred to polypropylene syringes 
(60 mL, Luer-Lok). By HPLC assays, the recovered cyclosporine in each sample was > 95% 
after 1 week stored at 25 °C, no significant physical changes were observed by visual 
inspection and particle size analysis. However, as shown in Figure 5.1 and Figure 5.2, a 
new impurity peak appeared at relative retention time of 1.45 (relative to the cyclosporine 
peak) after 24 h (performed on Waters HPLC system consisting of LDC Analytical 
ConstaMetric 3000 pump, Waters 717 plus autosampler, Waters 486 UV detector). 
 
Figure 5.1 HPLC chromatograms of intravenous cyclosporine 0.2 mg/mL in D5W stored in 
syringe at time zero, 24 h and 48 h. 
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Figure 5.2 HPLC chromatograms of intravenous cyclosporine 0.2 mg/mL in NS stored in 
syringe at time zero, 24 h and 48 h. 
As the impurity significantly increased with time, the polypropylene syringe stability 
study was terminated after 7 days. In the preliminary stability study on polypropylene 
polyolefin plastic containers, the new impurity peak was never observed. The impurity may 
not originate from plastic materials. The syringes used in this study are composed of plastic 
part-polypropylene and black part-latex-free rubber, and have a silicone lubricant coating in 
the inner surface. If the impurity is from silicone oil, the dissolution of oil would be fast 
and the impurity concentration would not increase with contact time.  It has been reported 
that surfactant- polysorbate 80 could leach additives from rubber stoppers in glass vials 
{Yu, 2010 #1144}. Therefore, plunger black tips may be the potential impurity origin. In 
order to confirm this hypothesis, a placebo solution corresponding to cyclosporine 
2.5mg/mL in 5% dextrose injection was prepared using polyoxyethylated castor oil 
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(Cremophor EL), alcohol, and 5% dextrose injection, and the rubber plunger tip was 
removed from syringe and immerged in the solution. 
 
Figure 5.3 HPLC chromatograms of intravenous cyclosporine (2.5 mg/mL in D5W) stored 
in syringe after 1 week (B) and  placebo solution ( Cremophor EL, ethanol, D5W) after 
exposition to syringe plunger tip  for 24h (A). 
 
Figure 5.4 HPLC chromatograms of initial placebo solution (A) and after exposition to 
syringe plunger tip for 24 h (B) 
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As illustrated in Figure 5.3 and Figure 5.4, the same impurity was detected only after 
one day of exposure, indicating the impurity was leached from the rubber tip. Moreover, 
another impurity peak was observed at retention time 4.5 min, which was not detected in 
intravenous cyclosporine preparations due to low sensitivity. It was concluded that some 
ingredients used in the manufacture of the black rubber of the syringe plunger could be 
leached by Cremophor EL. Even though the presence of impurities had no detrimental 
influence on the chemical stability of cyclosporine, the impurities constitute a potential 
toxicity hazard. The potential leachables maybe oligomers, antioxidants, and curing agents 
{Yu, 2010 #1144}. Considering the complexity of rubber composition, it is necessary to 
investigate the leachables when surfactant consisting formulations are contacting with 
rubber materials.  
As plastic syringes are commonly used to transfer intravenous drug in preparation 
of intravenous solutions, their compatibility with drug products could pose a health issue, 
especially if the formulation comprises surfactants. Thus, an additional test was performed 
to verify whether any additive leached from syringes during short periods of contact with 
intravenous cyclosporine. Undiluted intravenous cyclosporine (50 mg/mL) of 0.4 and 1 mL 
were stored in 1- and 5-mL polypropylene syringes for 10 minutes (each sample was 
prepared in triplicate).  The test samples were diluted with 5% dextrose injection to the 
concentration about 1 mg/mL of cyclosporine, and then assayed by HPLC with large 
volume of injection (100 µL, 25 times of amount of cyclosporine injected in general assay). 
As shown in Figure 5.5, the leaching impurities could not be detected. Thus, these syringes 
can be considered to be safe for sampling and transferring intravenous cyclosporine when 
the contact time is less than 10 minutes.  
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Figure 5.5 HPLC chromatogram of intravenous cyclosporine stored in syringe after 10 min  
diluted with D5W  injection to 1 mg/mL, injection volume 100 µL) 
 
5.3 Stability of intravenous cyclosporine stored in polypropylene-
polyolefin (PP-PO) and Ethylene-vinyl acetate (EVA) bags  
As discussed in Chapter 3, for all samples (0.2  mg/mL, 2.5 mg/mL in D5W and 
NS), the remaining cyclosporine was > 98% of initial after stored in PP-PO  bags for 14 
days. No changes were detected in the chromatograms after 14 days, illustrating 
intravenous cyclosporine was chemically stable during the storage at least 14 days. When 
stored in EVA bags for 14 days, the recovered cyclosporine was <  90% for diluted samples 
(0.2 mg/mL in D5W and NS) due to drug adsorption. Interestingly, no significant change in 
concentration was observed for the 2.5 mg/mL solutions. Surfactants are effective to reduce 
protein and peptide adsorption to PP surfaces (Duncan, Lee et al. 1995). In the 2.5 mg/mL 
solutions, the concentration of polyoxyethylated castor oil is 32.5 mg/mL, greater 
concentration of polyoxyethylated castor oil may reduce the adsorption of cyclosporine.  
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Table 5.1 Polymer structure of containers 
Material Structure Cyclosporine 
adsorption 
PVC 
 
Significant 
PP 
 
No 
EVA 
 
Significant 
 
The adsorption of hydrophobic drug to plastic is mainly driven by hydrophobic 
interactions; poorly soluble drugs are prone to partition on hydrophobic surface rather than 
in aqueous solution. Electrostatic interactions and hydrogen bonding also play a role in 
drug adsorption {Kambia, 2005 #1193;Palmgrén, 2006 #6}. Assuming the hydrophobic 
interactions play the major role, the adsorption of cyclosporine would occur on PP-PO 
surface, which is more hydrophobic than EVA surface. While in this study, significant 
adsorption was observed on EVA containers other than on PP-PO containers, implying that 
the adsorption is presumably dominated by electrostatic interactions caused by dipole-
dipole interaction or hydrogen-bonding. Even though cyclosporine is a highly hydrophobic 
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peptide, polar groups such as carbonyls and amides allow strong interaction with container 
surface.   
As shown in Table 5.1, EVA is a copolymer of ethylene and vinyl acetate. Ester 
groups in vinyl acetate units have potential to interact with cyclosporine by hydrogen bond 
or dipole-dipole attraction; while for PP-PO multilayer containers, PP polymer presents on 
the contact surface as out layer, similar interactions did not occur due to lack of polar 
groups. The adsorption of intravenous cyclosporine on PVC has been reported {Ptachcinski, 
1986 #488}, the cyclosporine ( 2 mg/mL in NS) loss was > 8% after stored for only 24 
hours. Beside, significant loss of cyclosporine injections in D5W and NS occurred when 
administrated through PVC sets. The presence of polar group-chloride may induce strong 
interactions with cyclosporine by dipole interactions.  
Drug adsorption depends on the vehicle and composition. Surfactants can be 
preferably adsorbed to polymer surface and inhibit drug adsorption. Ion strength and pH 
values also affect adsorption profiles {Palmgrén, 2006 #6}. In this study, it was found that 
cyclosporine adsorption in D5W is higher than in NS. On the contrary, more cyclosporine 
was adsorbed on PVC containers in NS than in D5W vehicle {Ptachcinski, 1986 #488}, 
indicating the  adsorption mechanisms on these two solvents are different.   
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6. Conclusion 
In this work, a methanol-based HPLC method has been developed and validated 
according to the guidance regulated in FDA, USP and ICH. The method was cost-effective 
and environmental favourable compared to the current acetonitrile-based USP method. This 
method was demonstrated to be stability-indicating and successfully applied in study of 
intravenous cyclosporine stability, examining leachables from syringe rubber.  
The compatibility of intravenous cyclosporine (0.2 mg/mL; 2 mg/mL in D5W or NS 
injections) with three types of non-PVC containers (PP-PO bags, PP syringes, EVA bags) 
has been investigated.  Polypropylene–polyolefin (PP-PO) bags are the best choice.  All 
preparations are stable for at least 14 days at 25 °C. As stored in polypropylene syringes 
with black rubber, some impurities were leached from rubber plunger tip. Therefore, 
polypropylene syringes with rubber parts could not be recommended.  However, these 
syringes were safe for preparation and transfer of intravenous cyclosporine solution if the 
contact time is < 10 minutes. Based on these results, it is proposed that the stability of 
surfactant- involved formulations should be highlighted when contacting with rubber 
packaging materials.  
EVA containers can be used to store cyclosporine of 0.2 mg/mL in D5W and NS 
injections less than 7 days and preparations of 2.5 mg/mL for 14 days. However, for diluted 
cyclosporine injections (0.2 mg/mL), significant adsorption on EVA bags was observed. 
The adsorption study showed that the internal diffusion maybe the rate-limiting step. The 
modified Weber-Morris model could successfully describe the adsorption process. In this 
study, a novel diffusion model based on internal diffusion was proposed regarding rapid 
adsorption, contact surface area and volume of solution. The model was numerically 
resolved and successfully used to predict long-term stability with variation < 2% ( the 
remaining concentration of cyclosporine measured vs the value predicted based on the 
model). 
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Appendix 
Supporting information of Chapter 4 
Fitting results of various models 
1. External diffusion model  
  
Adsorption amount vs contact time 
(cyclosporine injections in NS) 
Adsorption amount vs contact time 
(cyclosporine injections in D5W) 
 
2. Weber-Morris model  
  
Adsorption amount vs contact time 
(cyclosporine injections in NS) 
Adsorption amount vs contact time 
(cyclosporine injections in D5W) 
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3. Modified Weber-Morris model  
 
 
Adsorption amount vs contact time 
(cyclosporine injections in NS) 
Adsorption amount vs contact time 
(cyclosporine injections in D5W) 
 
4. Numerical Resolution of External+Internal Diffusion Model 
  
Adsorption amount vs contact time 
(cyclosporine injections in NS) 
Adsorption amount vs contact time 
(cyclosporine injections in D5W) 
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5. Numerical Resolution of Internal Diffusion Model 
 
 
Adsorption amount vs contact time 
(cyclosporine injections in NS) 
Adsorption amount vs contact time 
(cyclosporine injections in D5W) 
 
